

PCT

WORLD INTELLECTUAL
PROPERTY ORGANIZATION



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

WO 9603995A1

(51) International Patent Classification ⁶ : A61K 31/705, C07J 1/00	A1	(11) International Publication Number: WO 96/03995 (43) International Publication Date: 15 February 1996 (15.02.96)
(21) International Application Number: PCT/US95/09720 (22) International Filing Date: 3 August 1995 (03.08.95) (30) Priority Data: 08/285,438 4 August 1994 (04.08.94) US (71)(72) Applicant and Inventor: HOLICK, Michael, F. (US/US); 31 Bishop Lane, Sudbury, MA 01776 (US). (74) Agents: ESMOND, Robert, W. et al.; Sterne, Kessler, Gold- stein & Fox, Suite 600, 1100 New York Avenue, N.W., Washington, DC 20005-3934 (US).		(81) Designated States: CA, JP, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report.</i>
(54) Title: METHOD FOR DELIVERING ESTROGEN (57) Abstract The present invention relates to methods for the treatment or prevention of osteoporosis and the alleviation of the symptoms of menopause by the administration of an estrogen glycoside or estrogen orthoester glycoside.		

BEST AVAILABLE COPY

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

Method For Delivering Estrogen

Background of the Invention

Field of the Invention

The invention is in the field of Medicinal Chemistry.

5 *Related Art*

Menopause is defined as the final episode of menstrual bleeding in women. The term is also used colloquially to refer to the period of time encompassing the transitional period between the reproductive years up to and beyond the final episode of menstrual bleeding. For the purposes of this invention, reference to menopause will encompass this transitional period. Menopause is the result of the cessation of follicular development, which leads to a drop in the production of estradiol and other hormones. While 60% of estrogen formed in pre-menopausal women is in the form of estradiol, most of which is produced in the ovaries of ovulating women, post-menopausal ovaries produce a minimal amount of estrogen, with extraglandular tissues providing the majority of post-menopausal estrogen synthesis.

15 Symptoms associated with menopause include vasomotor instability (hot flashes), a decrease in breast size, atrophy of the urogenital epithelium and skin, and osteoporosis, a disease which is characterized by a marked loss of bone mass. Hot flashes may be accompanied by nervousness, anxiety, irritability and depression. Osteoporosis and the decrease in size of the female reproductive tract and breasts have been closely correlated to low levels of estrogen, while the pathology of hot flashes, though less well understood, may also be related to the decrease in estrogen production accompanying menopause.

20 The significant loss of bone mass which occurs at the time of menopause ultimately gives rise to osteopenia, which in turn gives rise to

-2-

spontaneous crush fractures of the vertebrae and fractures of the long bones. This disease is generally known as postmenopausal osteoporosis and presents a major medical problem, both in the United States and most other countries where the life-span of females reaches ages of at least 60 and 70 years. Generally the disease, which is often accompanied by bone pain and decreased physical activity, is diagnosed by one or two vertebral crush fractures with X-ray evidence of diminished bone mass. It is known that this disease is accompanied by diminished ability to absorb calcium, decreased levels of sex hormones, especially estrogen and androgens, and a negative calcium balance.


Methods for treating the disease have varied considerably but to date no really satisfactory treatment is yet being practiced. For example, calcium supplementation by itself has not been successful in preventing or curing the disease. Other treatments, for which variable results have again been reported, have included a combination of vitamin D in large doses, calcium and fluoride. The primary problem with this approach is that fluoride induces structurally unsound bone, called woven bone, and in addition, produces a number of side effects such as increased incidence of fractures and gastrointestinal reaction to the large amounts of fluoride administered.

Estrogen therapy is the most commonly used treatment of menopausal symptoms. Estrogen therapy ameliorates symptoms including hot flashes and atrophy of the urogenital epithelium and skin, and has positive effects on the incidence of osteoporosis.


Premarin is the most widely prescribed estrogen that is used for the treatment of postmenopausal symptoms, including osteoporosis, in the United States. Premarin is obtained from pregnant mares' urine, and contains the sodium salts of water-soluble estrogen sulphates as well as a variety of estrogen derivatives. One of the reasons that Premarin is so popular is because of concern that unconjugated estradiol, when given orally, has a first pass effect on the liver. This effect can have potentially serious consequences including the increase of blood clotting factors which can increase the user's risk of developing blood clots.

-3-

U.S. Patent No. 4,225,596 discloses methods for treating or preventing metabolic bone disease characterized by the loss of bone mass by administering at least one compound having the formulae (I) and (II):



(I)




(II)

5

where R₁, R₂, and R₄ are each selected from the group consisting of hydrogen, hydroxyl, lower alkyl, acyl and O-alkyl and R₃ is selected from the group consisting of hydrogen, hydroxyl, keto, lower alkyl, acyl and O-alkyl.

10

U.S. Patent No. 4,410,515 discloses the following compounds having Formula (III) which are active in maintaining calcium and phosphorus metabolism and are useful for treating hypocalcemia in animals:




(III)

wherein the bond between positions C-22 and C-23 is single or double; R² is hydrogen, CH₃ or CH₂CH₃; X is selected from the group consisting of hydrogen and -OR¹, where R¹ is hydrogen or a straight or branched chain glycosidic residue containing 1-20 glycosidic units per residue; with the proviso that at least one of the R¹ is glycosidic residue.

Fujimoto, *et al.* (Fujimoto *et al.*, *Experientia* 42:567-568 (1988)) reported the biochemical synthesis of 17β -estradiol-3-(β -D-glucoside) and 17α -estradiol-3-(α -D-glucoside) by incubation of 17β -estradiol with ovarian tissues from a silkworm. Similarly, incubation of 17α -estradiol 3-glucuronide with rabbit liver microsomes in the presence of uridine diphosphate glucose results in the synthesis of 17α -estradiol-17-(β -glucoside). (Williamson *et al.*, *Biochemistry* 8:45299-4304 (1969)). When 17β -estradiol-17-glucoside and 17α -estradiol-17-glucoside were injected into normal women, the 3-glucuronide derivatives of each compound were recovered in the urine (Williamson *et al.*, *Canadian J. Biochemistry* 50:958-962 (1972)).


Summary of the Invention

The present invention relates to a method for treating or preventing osteoporosis, as well as a method for alleviating the symptoms of menopause, in an animal having osteoporosis or susceptible to osteoporosis, or undergoing or having undergone menopause, comprising administering to the animal an effective amount of a compound having the Formula (IV):



(IV)

wherein R_1 and R_2 are independently hydrogen or a straight or branched chain glycosidic residue containing 1-20 glycosidic units per residue, or R_1 or R_2 is an orthoester glycoside moiety of the Formula (V):



(V)

wherein A represents a glycofuranosyl or glycopyranosyl ring;

R_3 is hydrogen, lower alkyl (C_1 - C_4), aralkyl (C_7 - C_{10}), or aryl, with the proviso that aryl is phenyl or phenyl substituted by chloro, fluoro, bromo, iodo, lower C_1 - C_4 alkyl, C_1 - C_4 alkoxy; or naphthyl;

R_4 is hydrogen or a straight or branched chain glycosidic residue containing 1-20 glycosidic units per residue; with the further proviso that at least one of R_1 and R_2 is either a glycosidic residue or an orthoester glycoside moiety.

Brief Description of the Figures

Figure 1A shows a reverse phase HPLC (2% H₂O/methanol, 1.5 ml/min) of ³H-vitamin D₃-glucoside after incubation with rat intestinal homogenate for 3 hours at 37°C. No ³H-vitamin D₃ was formed.


5 Figure 1B shows a reverse phase HPLC (2% H₂O/methanol, 1.5 ml/min) of ³H-vitamin D₃-glucoside after incubation with rat kidney homogenate for 3 hours at 37°C. Note the formation of ³H-vitamin D₃.

10 Figures 2A and 2B show the serum vitamin D concentration in human subjects after 3250 nmoles of either vitamin D₃ (2A) or vitamin D₃-glucoside (2B) was given orally.

Figure 3 shows the sequence of reactions for the synthesis of 17β-estradiol-3β-glucoside.

Description of the Preferred Embodiments


15 The invention is related to the discovery that compounds having Formula (IV) are useful in treating and preventing osteoporosis, as well as in alleviating the symptoms associated with menopause:



(IV)

20 wherein R₁ and R₂ are independently hydrogen or a straight or branched chain glycosidic residue containing 1-20 glycosidic units per residue, or R₁ or R₂ is an orthoester glycoside moiety of the Formula (V):

-7-



(V)

wherein A represents a glycofuranosyl or glycopyranosyl ring;

R₃ is hydrogen, lower alkyl (C₁-C₄), aralkyl (C₇-C₁₀), or aryl, with the proviso that aryl is phenyl or phenyl substituted by chloro, fluoro, bromo, iodo, lower C₁-C₄ alkyl, C₁-C₄ alkoxy; or naphthyl;

R₄ is hydrogen or a straight or branched chain glycosidic residue containing 1-20 glycosidic units per residue; with the further proviso that at least one of R₁ and R₂ is either a glycosidic residue or an orthoester glycoside moiety.

According to the invention, the symptoms of menopause which may be alleviated include atrophy of the urogenital epithelium and skin, decreased breast size, hot flashes and osteoporosis. Any animal which experiences any of these symptoms and which may benefit from the estradiol glycosides and orthoester glycosides of Formula IV may be treated according to the present invention. Preferred animals are of course humans, in particular, pre- or post-menopausal women. When administered to a pre-menopausal woman, it is possible to prevent osteoporosis. When administered to a post-menopausal woman, it is possible to reverse the adverse consequences of osteoporosis mentioned above, and arrest the further deterioration of the bones. Administration of these compounds during menopause can alleviate the occurrence of hot flashes, decreased breast size and atrophy of the urogenital tract and skin.

By glycosidic units are meant glycopyranosyl or glycofuranosyl, as well as their amino sugar derivatives. The residues may be homopolymers, random or alternating or block copolymers thereof. The glycosidic units have free hydroxy groups, or hydroxy groups acylated with a group R₅-(C=O)-, wherein R₅ is hydrogen, lower C₁₋₆ alkyl, C₆₋₁₀ substituted or unsubstituted aryl or C₇₋₁₆ aralkyl. Preferably, the acyl groups are acetyl or propionyl. Other

preferred groups are where R_3 is phenyl, nitrophenyl, halophenyl, lower alkyl substituted phenyl, lower alkoxy substituted phenyl, and the like or benzyl, lower alkoxy substituted benzyl and the like.

5 The compounds useful in the practice of the invention contain at least one glycoside or orthoester glycoside residue at positions 3 or 17. They may contain, however, two glycoside or orthoester glycoside residues simultaneously. Preferably, the glycosides or orthoester glycosides are linked through the 1-carbon to the 3- or 17-position on estradiol.

10 The glycosides can comprise up to 20 glycosidic units. Preferred, however, are those having less than 10, most preferred, those having 3 or less than 3 glycosidic units. Specific examples are those containing 1 or 2 glycosidic units in the glycoside residue.

15 The glycopyranose or glycofuranose rings or amino derivatives thereof may be fully or partially acylated or completely deacylated. The completely or partially acylated glycosides are useful as defined intermediates for the synthesis of the deacylated materials.

20 Among the possible glycopyranosyl structures are glucose, mannose, galactose, gulose, allose, altrose, idose, or talose. Among the furanosyl structures, the preferred ones are those derived from fructose, arabinose or xylose. Among preferred diglycosides are sucrose, cellobiose, maltose, lactose, trehalose, gentiobiose, and melibiose. Among the triglycosides, the preferred ones may be raffinose or gentianose. Among the amino derivatives are N-acetyl-D-galactosamine, N-acetyl-D-glucosamine, N-acetyl-D-mannosamine, N-acetylneuraminic acid, D-glucosamine, lyxosylamine, D-galactosamine, and the like.

25 When more than one glycosidic unit is present on a single hydroxy group (i.e., di or polyglycosidic residues), the individual glycosidic rings may be bonded by 1-1, 1-2, 1-3, 1-4, 1-5 or 1-6 bonds, most preferably 1-2, 1-4 and 1-6. The linkages between individual glycosidic rings may be α or β .

30 The water soluble glycosidic derivatives of the aforementioned compounds may be obtained according to the general methods set disclosed

in Holick, U.S. Patent 4,410,515, the contents of which are fully incorporated by reference herein. The estradiol glycosyl orthoester compounds may be obtained according to U.S. Patent 4,521,410, the contents of which are fully incorporated by reference herein. Preferred estradiol glycosyl orthoesters are
5 3-estradiol-17 β -(α -D-glucopyranosyl-1',2'-orthoacetate) and 17 β -estradiol-3- β -glucopyranosyl-1',2'-orthoacetate.

The compounds of the invention can be administered in any appropriate pharmaceutically acceptable carrier for oral, parenteral, or topical administration. They can be administered by any means that treats or prevents
10 osteoporosis or alleviates the symptoms of menopause in animals, especially humans. The dosage administered will be dependent upon the age, health and weight of the recipient, kind of concurrent treatment, if any, frequency of treatment and the nature of the effect desired. For example, systemic daily dosage of 3-(β -glucopyranosyl)-17 β -estradiol is from about 0.001
15 milligrams/kg to 100 milligrams/kg, preferably 0.01 to 1.0 milligrams per kg of body weight. Normally, from about 0.01 to 0.1 milligrams/kg per day of the glycoside or orthoester glycoside, in one or more dosages per day is effective to obtain the desired results. One of ordinary skill in the art can determine the optimal dosages and concentrations of other active estradiol,
20 vitamin D glycoside and orthoester glycoside compounds with only routine experimentation.

The compounds can be employed in dosage forms such as tablets, capsules or powder packets, or liquid solutions, suspensions or elixirs for oral administration, as well as sterile liquid for formulations such as solutions or
25 suspensions for parenteral use. The compounds could also be administered via topical patches, ointments, gels or other transdermal applications. In such compositions, the active ingredient will ordinarily be present in an amount of at least 1.0% by weight based upon the total weight of the composition, and not more than 90% by weight. An inert pharmaceutically acceptable carrier
30 is preferably used. Among such carriers include 95% ethanol, vegetable oils, propylene glycols, saline buffers, etc.

It is well recognized that β -glucosidases do not exist in the small intestine because, if they did, humans would be able to digest cellulose as do ruminants. A study was conducted whereby ^3H -vitamin D_3 - 3β -glucoside was incubated with intestine and kidney homogenates. It was found that only the kidney homogenate was capable of removing the glucoside from vitamin D_3 . None of the vitamin D_3 - 3β -glucoside was metabolized in the intestinal homogenates. See Figure 1. Therefore, the same results for estradiol- 3β -glucoside would be expected since vitamin D and estradiol are both fat soluble sterols.

Since the small intestine does not contain β -glucosidases, it would not be expected that the liver would receive free estradiol coming from the intestine after the oral ingestion of estradiol-3-(β -glucoside). Thus, this would lessen the first pass effect of estradiol-3-(β -glucoside) when compared to estradiol itself.

In vivo rat studies have shown that when estradiol-3-(β -glucoside) was given orally for two weeks to ovariectomized rats, estradiol was found in the circulation (Table 1). Thus, the non-specific β -glucosidases found in peripheral tissues appear to be responsible for the de-conjugation of estradiol-3-(β -glucoside) to estradiol. As shown in Figure 1, a study with the vitamin D - 3β -glucoside as a model compound was conducted which shows that β -glucosidase(s) in the kidney are able to de-conjugate the β -glucoside from the vitamin D - 3β -glucoside.

One of the potential side-effects of giving estradiol orally is its first pass biologic effect on the liver especially as it relates to increasing the synthesis of proteins associated with blood clotting. Since there is evidence that estradiol-3-(β -glucoside) does not interact with the estradiol receptor, it would be expected that the estradiol-3-(β -glucoside) would not have the same potency of activity in increasing blood clotting factors in the liver as estradiol itself.

De-conjugation of estradiol-3-(β -glucoside) to estradiol will occur slowly in peripheral tissues, and therefore, will maintain circulating levels of

estradiol at a more physiologic level for a longer period of time. A study in humans with the vitamin D-3 β -glucoside was conducted as a model compound. The blood level of vitamin D after an equimolar dose of vitamin D₃ and vitamin D₃-3 β -glucoside was compared. As can be seen in Figure 2, the blood levels of vitamin D₃ resulting from the de-conjugation of its glucoside is about 30% of that achieved when the same dose of vitamin D₃ was given orally. Thus, from this single dose vitamin D-glucoside study, there would not appear to be any hazard to the prolonged duration of action of the estradiol resulting from the slow de-conjugation of the estradiol-3-(β -glucoside). A study in ovariectomized rats was also conducted to determine the blood level of estradiol and estrone after receiving three different doses of either estradiol or estradiol-3-(β -glucoside) orally each day for two weeks. As can be seen in Table 1, the circulating estradiol levels in the rats receiving either 1, 10 or 15 nmol of estradiol-3-(β -glucoside) were comparable or lower to the rats receiving the same doses of estradiol. Thus, estradiol-3-(β -glucoside) will increase circulating concentrations of estradiol.

Based on the results in rats and humans with the model vitamin D-3 β -glucoside and experience with giving estradiol-3-(β -glucoside) to ovariectomized rats, there is no indication of potential additive or multiplicative toxicity. Indeed, in the study where oral administration of estradiol-3-(β -glucoside) to ovariectomized rats was evaluated for a period of two weeks, it was found that the β -estradiol levels were either no different or lower compared to the animals that received unconjugated estradiol (Table 1). No untoward side-effects or vaginal bleeding was noted in either group of rats.

Having now generally described this invention, the same will be understood by reference to the following examples which are provided herein for purposes of illustration only and are not intended to be limiting unless otherwise specified.

Example 1

The synthesis of 17 β -estradiol-3-(β -glucoside)

17 β -Estradiol-3- β -glucoside was synthesized as outlined in Figure 3. Estrone was coupled with acetobromoglucose in the presence of cadmium carbonate (CdCO₃) as a catalyst following the procedure of Conrow and Bernstein (Conrow and Bernstein, *J. Org. Chem.* 36:863-870 (1971)). The estrone 3 β -2'3',4',6'-tetra-O-acetyl-D-glucopyranoside (A) was the predominant product (> 60%) of the reaction and was obtained by crystallization. The melting point of the product was 212-214°C (reported mp 212-216°C) (Conrow and Bernstein, *J. Org. Chem.* 36:863-870 (1971)). The IR and NMR spectra of this product matched that of reported values (Conrow and Bernstein, *J. Org. Chem.* 36:863-870 (1971)).

The estrone conjugate (A) was reduced with sodium borohydride at 0°C in methanol-THF. This reduction resulted in the stereo specific formation of the 17 β -alcohol (Hobkirk et al., *J. Clin. Endocrinol.* 32:476-480 (1971)). The product (B) was obtained in almost quantitative yield after preparative TLC purification from silica plates (2:1 hexane-ethyl acetate).

Compound B was treated with methanolic ammonia at 4°C. Removal of the solvent and trituration with water produced a white crystalline solid, mp 210-220°C. The yield of the product (C), 17 β -estradiol-3 β -glucoside was quantitative. The HPLC analysis of the product (C₁₈-column, 20% water in methanol, 0.5 ml/minute, monitored with a UV detector set at 254 nm) produced a single peak which demonstrated its homogeneity. Interpretation of NMR and mass spectrum data is given below.

Example 2

Physico-Chemical Analysis of 17 β -Estradiol-3 β -Glucoside (C)

The UV absorption spectrum for compound C in methanol had a typical spectrum for estradiol, wherein $\lambda_{\max} = 280$ nm.

5 For the mass spectrum and NMR analysis of compound C, it was converted to its penta-O-acetyl derivative by treatment with pyridine-acetic anhydride-catalytic amount of 4,4'-dimethylaminopyridine. The reaction product was homogeneous on TLC and was purified by HPLC on a silica column with 5% isopropanol in n-hexane at 1 ml/minute. The isolated
10 compound was analyzed by FABMS and NMR:

FABMS: 662.6, 643.5, 332.3, 331.3, 288.4.

NMR: (200 MHz;CDCl₃ solvent, TMS internal standard) δ 7.28 (overlapped with 7.26 peak of CHCl₃, aromatic H); δ 6.85 (m, aromatic H, 2H), δ 5.15 (m, 4H, H-1', 2', 3', 4'), δ 4.56 (d, J=9 Hz; 1H, 17-CH); δ 4.2
15 (m, 2H, 6'-CH₂), δ 3.72 (m, 1H, 5'-CH); δ 2.85 (m, 2H, H-6-CH₂); δ 2.3 and 2.2 (5 singlets, 15 H, 5-OAc-protons); δ 0.75 (s, 3H, 18-CH₃).

Example 3

In vivo Rat Studies

In vivo rat studies were carried out where estradiol-3-(β -glucoside) was
20 given orally for two weeks to ovariectomized rats. Estradiol was detected in the circulation by radioimmunoassay, using a kit purchased from ICN Biomedical (Costa Mesa CA, 92626). The results are shown in Table 1.

Table 1

Circulating concentration of 17β -estradiol and estrone in six ovariectomized rats per group that received an oral dose of either 17β -estradiol or 17β -estradiol-3 β -glucoside (estradiol-glc) each day for two weeks.


	Compounds	Dose (nmol)	Blood Concentrations	(pg/ml)
			Estradiol	Estrone
1.	control	0	3.2 ± 0.5	22.7 ± 3.6
2.	estradiol	1	3.5 ± 0.7	17.8 ± 2.0
3.	estradiol	10	8.7 ± 2.1	18.5 ± 2.9
4.	estradiol	15	46.8 ± 10.4	19.8 ± 7.0
5.	estradiol-glc	1	3.8 ± 0.7	12.2 ± 1.5
6.	estradiol-glc	10	7.7 ± 2.1	12.8 ± 1.5
7.	estradiol-glc	15	12.3 ± 3.4	11.5 ± 0.7

As can be seen in Table 1, the circulating estradiol levels in the rats receiving either 1, 10 or 15 nmol of estradiol-3-(β -glucoside) were comparable or lower to the rats receiving the same doses of estradiol.


From the foregoing description, one skilled in the art can easily ascertain the essential characteristics of this invention, and without departing from the spirit and scope thereof, can make various changes and modifications of the invention to adapt it to various usages and conditions without undue experimentation. All patents and publications cited herein are incorporated by reference in their entirety.

What is Claimed is:

1. A method for treating or preventing osteoporosis in an individual having osteoporosis or susceptible to osteoporosis, comprising administering to said individual an effective amount of a compound having the formula:



wherein R_1 and R_2 are independently hydrogen or a straight or branched chain glycosidic residue containing 1-20 glycosidic units per residue, or R_1 or R_2 is an orthoester glycoside moiety of the formula:




wherein A represents a glycofuranosyl or glycopyranosyl ring;

R_3 is hydrogen, lower alkyl (C_1 - C_4), aralkyl (C_7 - C_{10}), or aryl, with the proviso that aryl is phenyl or phenyl substituted by chloro, fluoro, bromo, iodo, lower C_1 - C_4 alkyl, C_1 - C_4 alkoxy; or naphthyl;

R_4 is hydrogen or a straight or branched chain glycosidic residue containing 1-20 glycosidic units per residue; with the further proviso that at least one of R_1 and R_2 is either a glycosidic residue or an orthoester glycoside moiety.


2. A method for alleviating the symptoms of menopause in an individual undergoing or having undergone menopause, comprising administering to said individual an effective amount of a compound having the formula:

-16-



wherein R_1 and R_2 are independently hydrogen or a straight or branched chain glycosidic residue containing 1-20 glycosidic units per residue, or R_1 or R_2 is an orthoester glycoside moiety of the formula:

5



wherein A represents a glycofuranosyl or glycopyranosyl ring;

R_3 is hydrogen, lower alkyl (C_1 - C_4), aralkyl (C_7 - C_{10}), or aryl, with the proviso that aryl is phenyl or phenyl substituted by chloro, fluoro, bromo, iodo, lower C_1 - C_4 alkyl, C_1 - C_4 alkoxy; or naphthyl;

10

R_4 is hydrogen or a straight or branched chain glycosidic residue containing 1-20 glycosidic units per residue; with the further proviso that at least one of R_1 and R_2 is either a glycosidic residue or an orthoester glycoside moiety.

15

3. The method of claim 1 or 2, wherein said compound is 17 β -estradiol-3-(β -glucoside).

4. The method of claim 1 or 2, wherein said compound is administered in an amount ranging from about 0.01 to 10 milligrams/kg per day.


-17-

5. The method of claim 1 or 2, wherein said compound is administered as part of a pharmaceutical composition comprising a pharmaceutically acceptable carrier.


6. The method of claim 1, wherein said individual is suffering from or has suffered from menopause.

7. The method of claim 1 or 2, wherein said compound is administered to a woman prior to the onset of menopause.

8. A compound having the formula:



wherein R₁ is hydrogen, a straight or branched chain glycosidic residue containing 1-20 glucosidic units per residue, or an orthoester glycoside moiety of the formula:



wherein A represents a glycofuranosyl or glycopyranosyl ring;

R₃ is hydrogen, lower alkyl (C₁-C₄), aralkyl (C₇-C₁₀), or aryl, with the proviso that aryl is phenyl or phenyl substituted by chloro, fluoro, bromo, iodo, lower C₁-C₄ alkyl, C₁-C₄ alkoxy; or naphthyl;

R₄ is hydrogen or a straight or branched chain glycosidic residue containing 1-20 glycosidic units per residue; and

R_2 is an orthoester glycoside residue having the above formula, or a hydrogen when R_1 is an orthoesterglycoside moiety.

9. The compound of claim 8 which is 3-estradiol-17 β -(α -D-glucopyranosyl-1',2'-orthoacetate).

5 10. The compound of claim 8 which is 17 β -estradiol-3- β -glucopyranosyl-1',2'-orthoacetate.

1/4




FIG. 1A




FIG. 1B

RECTIFIED SHEET (RULE 91)

2/4




FIG. 1C

RECTIFIED SHEET (RULE 91)

3/4




FIG. 2A




FIG. 2B

RECTIFIED SHEET (RULE 91)

4/4




FIG. 3

RECTIFIED SHEET (RULE 91)

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US95/09720

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : A61K 31/705; C07J 1/00

US CL : 514/26; 536/5; 552/502

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 514/26; 536/5; 552/502

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

HCAPlus, BIOSIS, MEDLINE, APS


search terms: menopause, osteoporosis, estradiol [50-28-2]

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X --- Y	Biochemistry, Volume 8, Number 11, issued November 1969, Williamson et al., "Isolation of 17 α -Estradiol 17- β -D-Glucopyranoside from Rabbit Urine, and Its Synthesis and Characterization", pages 4299-4304, see entire document.	8-10 ---- 1-7
X --- Y	Experientia, Volume 42, issued 1986, Fujimoto et al., "Characterization of 17 β -estradiol 3-(β -D-glucopyranoside) and 17-(α -D-glucopyranoside) as the metabolites of 17 β -estradiol in the cultured ovaries of the silkworm, <i>Bombyx mori</i> ", pages 567-568, see entire document.	8-10 ---- 1-7
Y	Gilman et al., "Goodman and Gilman's The Pharmacological Basis of Therapeutics", Eighth Edition, published 1990 by Pergamon Press, Inc. (Maxwell House, Fairview Park, Elmsford, NY), pages 1390-1395, see entire document.	1-7

☒ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	T	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principles or theory underlying the invention
A document defining the general state of the art which is not considered to be of particular relevance	X*	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
E earlier document published on or after the international filing date	Y*	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	A*	document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means		
P document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search 11 OCTOBER 1995	Date of mailing of the international search report 25 OCT 1995
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703) 305-3230	Authorized officer HOWARD C. LEE  Telephone No. (703) 308-0196

Form PCT/ISA/210 (second sheet)(July 1992)*

INTERNATIONAL SEARCH REPORT


International application No.

PCT/US95/09720

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US, A, 4,078,060 (BENSON ET AL.) 07 March 1978, see entire document.	1-10
A	US, A, 4,096,254 (BENSON ET AL.) 20 June 1978, see entire document.	1-10
A	US, A, 5,183,814 (DUKES) 02 February 1993, see entire document.	1-10

Form PCT/ISA/210 (continuation of second sheet)(July 1992)*



(19)

Europäisches Patentamt

European Patent Office

Office européen des brevets



(11)

EP 0 890 643 A2

(12)

EUROPEAN PATENT APPLICATION

(43) Date of publication:
13.01.1999 Bulletin 1999/02

(21) Application number: 98112865.5

(22) Date of filing: 10.07.1998

(51) Int. Cl.⁶: C12N 15/53, C12N 9/02,
C07K 16/40, A61K 39/395,
A61K 38/44, C12Q 1/68,
C12Q 1/26

(84) Designated Contracting States:
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE
Designated Extension States:
AL LT LV MK RO SI

(30) Priority: 10.07.1997 JP 185399/97
25.11.1997 JP 322651/97

(71) Applicant:
KYOWA HAKKO KOGYO KABUSHIKI KAISHA
Chiyoda-ku, Tokyo 100 (JP)

(72) Inventors:
• Anazawa, Hideharu
Tokyo 178-0064 (JP)
• Shimada, Hiroko
Tokyo 162-0041 (JP)
• Sugimoto, Seiji
Hachioji-shi, Tokyo 192-0363 (JP)

(74) Representative:
VOSSIUS & PARTNER
Siebertstrasse 4
81675 München (DE)

(54) 25-Hydroxyvitamin D₃-1 α -hydroxylase and dna encoding the hydroxylase

(57) The present invention relates to a polypeptide having 25-hydroxyvitamin D₃-1 α -hydroxylase activity, being useful for the prevention, diagnosis and therapeutic treatment of adult diseases such as osteoporosis induced by the decrease of active type vitamin D₃ and catalyzing the final stage of vitamin D₃ activation; and the gene encoding the polypeptide.

In accordance with the present invention, the following can be provided; a polypeptide having 25-hydroxyvitamin D₃-1 α -hydroxylase activity, DNA encoding the polypeptide, a recombinant DNA prepared by inserting the DNA in a vector, a transformant carrying the recombinant DNA, a method for preparing 25-hydroxyvitamin D₃-1 α -hydroxylase by using the transformant, a method for preparing 1 α , 25-dihydroxyvitamin D₃ comprising using the polypeptide having 25-hydroxyvitamin D₃-1 α -hydroxylase activity, and an antibody recognizing the polypeptide.

EP 0 890 643 A2

Description

The present invention relates to a polypeptide having 25-hydroxyvitamin D₃-1 α -hydroxylase activity, DNA encoding the polypeptide, a recombinant DNA prepared by inserting the DNA in a vector, a transformant carrying the recombinant DNA, a method for preparing 25-hydroxyvitamin D₃-1 α -hydroxylase by using the transformant, a method for preparing 1 α , 25-dihydroxyvitamin D₃ by using the polypeptide having 25-hydroxyvitamin D₃-1 α -hydroxylase activity and to an antibody recognizing the polypeptide.

Active type vitamin D₃ has been known as a hormone having various biological activities such as the activity of controlling calcium metabolism, the induction of cellular differentiation, and immunomodulation.

It has been known that active type vitamin D₃ is generated from vitamin D₃ having no biological activities through the metabolism in biological organisms.

As one of the action mechanisms of active type vitamin D₃, an action mechanism through cytoplasmic receptors has been known.

It has been known that active type vitamin D₃ is essentially 1 α , 25-dihydroxyvitamin D₃ wherein the positions 1 α and 25 have been hydroxylated. As to the metabolic pathway for the activation, it has been known that vitamin D₃ is firstly modified into 25-hydroxyvitamin D₃ by introducing a hydroxyl group into the position 25 and the position 1 α of the resulting 25-hydroxyvitamin D₃ is hydroxylated to form 1 α , 25-dihydroxyvitamin D₃ [All of vitamin D₃, edited by Etsuro Ogata, Tateo Suda, and Yosuke Ogura, Kodansha Scientific, Co. (1993)].

As 25-hydroxylase gene which functions to introduce a hydroxyl group into the position 25, a gene derived from rat liver has been cloned (Japanese Published Unexamined Patent Application No.2324893/1991). Furthermore, the gene of the hydroxylase of the position 24 of vitamin D₃ has been cloned [Japanese Published Unexamined Patent Application No.207196/1992].

As an enzyme to hydroxylate the position 1 α of vitamin D₃, human CYP27 has been reported [Proc. Natl. Acad. Sci., USA, 91, 10014 (1994)], but the activity of the enzyme to hydroxylate the position 1 α is a secondary activity, so the activity is very weak, which is not an essential activity. Additionally, the activity is not inducible.

It has been known that 25-hydroxyvitamin D₃-1 α -hydroxylase activity is induced in the kidneys of rats and chickens fed with vitamin D₃ deficient diet [Gerontology, 42 (Supplement 1), 67-77 (1996)].

Up to now, no report has been presented yet in any of animal species, concerning the isolation of any enzyme polypeptide catalyzing the final stage of vitamin D₃ activation to hydroxylate the most significant position 1 α , or the isolation of a gene encoding the polypeptide.

As a method for producing 1 α , 25-dihydroxyvitamin D₃, a method comprising the use of kidney homogenates or mitochondria fractions of animals such as chicken has been known [Nature, 230, 228 (1971); J. Biol. Chem., 247, 7528 (1972); Biochemistry, 25, 5512 (1986)], but the method requires a vast amount of animal kidney or liver and demands laborious works to prepare them, so the method is insufficient and is not practical. It has been found a microorganism having activity to directly induce hydroxyl groups into the positions 1 α and 25 (Japanese Published Examined Patent Application No.64678/1992), but the activity is very weak and substrate specificity is low, so it is difficult to separate the product and byproducts.

Thus, the technical problem underlying the present invention was to solve the above-mentioned problems in the prior art.

The solution to the technical problem is provided by the embodiments characterized in the claims.

Accordingly, the present invention provides a polypeptide having 25-hydroxyvitamin D₃-1 α -hydroxylase activity and a gene encoding the polypeptide. 25-hydroxyvitamin D₃-1 α -hydroxylase catalyzes the final stage of vitamin D₃ activation, and is useful for prevention, diagnosis and therapeutic treatment of diseases such as osteoporosis induced by the decrease of active type vitamin D₃.

The present invention relates, in addition, to a polypeptide having 25-hydroxyvitamin D₃-1 α -hydroxylase activity and DNA encoding the polypeptide, to a recombinant DNA prepared by inserting the DNA in a vector, a transformant carrying the recombinant DNA, a method for producing 25-hydroxyvitamin D₃-1 α -hydroxylase or a polypeptide having 25-hydroxyvitamin D₃-1 α -hydroxylase activity by using the transformant, a method for producing 1 α , 25-dihydroxyvitamin D₃ by using the polypeptide having 25-hydroxyvitamin D₃-1 α -hydroxylase activity and an antibody recognizing the polypeptide.

The figure shows:

Fig.1 is an HPLC chart of the identified vitamin D₃ metabolites in cells to which pcMD3R or pcDNA3 is introduced, wherein "A" shows the results of the identification of vitamin D₃ metabolites in the cells to which pcMD3R is introduced; and "B" represents the results of vitamin D₃ metabolites in the cells to which pcDNA3 is introduced, wherein (1) represents 25-hydroxyvitamin D₃; (2) represents 24, 25-dihydroxyvitamin D₃; (3) represents 10-oxo-19-nor-25-hydroxyvitamin D₃ and (4) represents 1 α , 25-dihydroxyvitamin D₃.

As the polypeptide of the present invention, any polypeptide having 25-hydroxyvitamin D₃-1 α -hydroxylase activity may be used, for example including a polypeptide having an amino acid sequence selected from amino acid sequences represented by SEQ ID NOS.1 and 2, or having an amino acid sequence in which one or more amino acid residues are deleted, substituted and/or added in the amino acid sequence of a polypeptide, the amino acid sequence being selected from amino acid sequences represented by SEQ ID NOS. 1 and 2, and having 25-hydroxyvitamin D₃-1 α -hydroxylase activity.

The polypeptide having an amino acid sequence in which one or more amino acid residues are deleted, substituted or added in the amino acid sequence, the amino acid sequence being selected from amino acid sequences represented by SEQ ID NOS.1 and 2, and having 25-hydroxyvitamin D₃-1 α -hydroxylase activity may be prepared according to the method described in Nucleic Acids Research, 10, 6487 (1982); Proc. Natl. Acad. Sci., USA, 79, 6409 (1982); Proc. Natl. Acad. Sci., USA, 81, 5662 (1984); Science, 224, 1431 (1984); PCT WO85/00817 (1985); Nature, 316, 601 (1985); Gene, 34, 315 (1985); Nucleic Acids Research, 13, 4431 (1985); Current Protocols in Molecular Biology, Chapter 8. Mutagenesis of Cloned DNA, John Wiley & Sons, Inc. (1989); and the like.

DNA of the present invention includes DNA encoding the polypeptide of the present invention, for example, DNA encoding the polypeptide having an amino acid sequence selected from amino acid sequences represented by SEQ ID NOS.1 and 2, DNA encoding the polypeptide having an amino acid sequence in which one or more amino acid residues are deleted, substituted or added in the amino acid sequence selected from amino acid sequences represented by SEQ ID NOS.1 and 2, and having 25-hydroxyvitamin D₃-1 α -hydroxylase activity, DNA comprising a nucleotide sequence selected from SEQ ID NOS.3 and 4, or DNA hybridizable with these DNAs under stringent conditions.

In the present application, "DNA hybridizable under stringent conditions" means DNA recovered by using the DNA encoding the polypeptide having 25-hydroxyvitamin D₃-1 α -hydroxylase activity as a probe through colony hybridization, plaque hybridization or Southern blot hybridization or the like, specific example of which includes DNA identified by hybridization in the presence of 0.7 to 0.1 M NaCl at 65 °C by using a filter on which a DNA prepared from colonies or plaques is immobilized and then rinsing the filter at a condition of 65 °C by using 0.1 to 2 x SSC solutions (the composition of 1 x SSC solution is as follows; 150 mM NaCl and 15 mM sodium citrate).

The hybridization can be carried out according to the method described in Molecular Cloning, A Laboratory Manual, 2-nd edition, Sambrook, Fritsch & Maniatis, eds., Cold Spring Harbor Laboratory Press (1989) (referred to as "Molecular Cloning, 2-nd edition" hereinafter), Current Protocols in Molecular Biology, Supplement 1 to 34, DNA Cloning 1: Core Techniques, A Practical Approach, Second Edition, Oxford University (1995) or the like. Hybridizable DNA includes for example DNA having homology of 60% or more, preferably 80% or more, more preferably 95 % or more to the nucleotide sequence of the DNA encoding the polypeptide having an amino acid sequence selected from amino acid sequences represented by SEQ ID NOS.1 and 2.

The antibody of the present invention includes antibodies recognizing the polypeptide described above.

In a further embodiment the present invention relates to 25-hydroxyvitamin D₃-1 α -hydroxylase or a polypeptide having 25-hydroxyvitamin D₃-1 α -hydroxylase activity obtainable by the method of the present invention.

Furthermore, the present invention relates to a pharmaceutical composition comprising the polypeptide, the DNA, the recombinant DNA, and/or the antibody of the present invention, and, optionally, a pharmaceutically acceptable carrier and/or diluent.

In yet another embodiment the present invention relates to a diagnostic composition comprising the polypeptide, the DNA, the recombinant DNA, and/or the antibody of the present invention.

The present invention also relates to the use of the polypeptide, the DNA, and/or the recombinant DNA of the present invention for the preparation of a pharmaceutical composition for preventing or treating a disease characterized by a decrease of active type vitamin D₃.

In a preferred embodiment of the use of the present invention, said disease is osteoporosis.

In a further embodiment the present invention relates to a kit comprising: the polypeptide, the DNA, the recombinant DNA, and/or the antibody of the present invention.

1) Preparation of cDNA library from mRNA derived from rat kidney

From tissues, for example kidney of a rat fed with vitamin D₃ deficient diet to induce 25-hydroxyvitamin D₃-1 α -hydroxylase activity, mRNA [sometimes referred to as poly(A)⁺RNA] is prepared.

Method for preparing such mRNA includes a method comprising preparing the whole RNA from the rat tissues and preparing then mRNA as poly(A)⁺RNA by using the oligo (dT) immobilized cellulose column method [Molecular Cloning, 2-nd edition]; a method comprising directly preparing mRNA from rat tissues by using kits such as Fast Track mRNA Isolation kit manufactured by Invitrogen, Co, and Quick Prep mRNA Purification Kit, manufactured by Pharmacia, Co. and the like.

Method for preparing the whole RNA includes thiocyanate guanidine-trifluoroacetic acid cesium method [Methods in Enzymol., 154, 3 (1987)], AGPC method [Experimental Medicine, 9, 1937 (1991)] and the like.

The whole RNA and mRNA may be prepared from rat tissues with no induction of 25-hydroxyvitamin D₃-1 α -hydroxylase activity by similar method described above.

By using the mRNA prepared above, a cDNA library is prepared by a conventional method.

Method for preparing the cDNA library includes for example a method for preparing a cDNA library, comprising synthesizing cDNA from the mRNA derived from the kidney resected from a rat with 25-hydroxyvitamin D₃-1 α -hydroxylase activity induced, by using ZAP-cDNA synthesis kit manufactured by Stratagene, Co., cDNA Synthesis System manufactured by GIBCO BRL, Co. and the like, ligating then an adapter with a digestible site with an appropriate restriction enzyme, digesting a cloning vector λ ZAP II with the restriction enzyme, and inserting the cDNA into the digested site of the cloning vector.

As the cloning vector to prepare the cDNA library, any cloning vector capable of autonomously replicating in *Escherichia coli* K12 may be used.

The cloning vector includes for example phage vector, plasmid vector and the like, preferably including λ ZAP II described above, in addition to pUC18, pBluescript (Stratagene, Co.) and the like.

As a host microorganism, any microorganism of species *Escherichia coli* may be used, preferably including *Escherichia coli* XL1-Blue, *Escherichia coli* XL2-Blue, *Escherichia coli* DH1, *Escherichia coli* MC1000 and the like.

2) Selection of an amino acid sequence characteristic to vitamin D₃ hydroxylase

Screening a region with the amino acid sequence present in common with both the hydroxylase of the position 25 of rat vitamin D₃ [Japanese Published Unexamined Patent Application No.232493/1991] and the hydroxylase of the position 24 thereof (Japanese Published Unexamined Patent Application No.207196/1992), the amino acid sequence present in the region is selected as the amino acid sequence characteristic to the hydroxylase of vitamin D₃.

The region with the amino acid sequence includes for example adrenodoxin binding region (referred to as "Region A" hereinafter), heme binding region (referred to as "Region H" hereinafter) and the like.

3) Amplification of a partial fragment of DNA encoding 25-hydroxyvitamin D₃-1 α -hydroxylase

Based on the amino acid sequence of the region selected in 2) above and with reference to the codons of rat, a sense primer and an antisense primer are designed and prepared, which are appropriate for the amplification of the DNA encoding 25-hydroxyvitamin D₃-1 α -hydroxylase by polymerase chain reaction (referred to as "PCR" hereinafter).

Such primers include DNA comprising a nucleotide sequence selected from nucleotide sequences represented by SEQ ID NOS.7, 8 and 9.

Using the mRNA recovered in 1), first strand DNA is synthesized by reverse transcriptase reaction. DNA synthesis may be carried out using a cDNA synthetic kit manufactured by Stratagene, Co.

Using the first strand DNA as a template and utilizing the sense primers and antisense primers as prepared above, RT (reverse transcription)-PCR is carried out to amplify a DNA region containing a part of DNA encoding 25-hydroxyvitamin D₃-1 α -hydroxylase.

Using the RT-PCR amplified fragments and 3' RACE system kit manufactured by BRL, Co., PCR amplification is carried out between the RT-PCR amplified fragment and the 3-terminal poly(A) structure to recover a longer PCR amplified fragment additionally containing the noncoding region on 3' side.

More specifically, a PCR amplified fragment containing the 3' noncoding region can be recovered by synthesizing cDNA using the mRNA recovered in 1) and the oligo dT/AUAP primer in the 3' RACE system kit manufactured by BRL, CO. and conducting PCR amplification using the DNA as a template and using the AUAP primer in the 3' RACE system kit manufactured by BRL and the RT-PCR amplified fragment.

Using 5' RACE method in the same manner, a PCR amplified fragment containing the 5' region can be recovered.

It can be confirmed that the amplified DNA fragment is a partial fragment of the DNA encoding 25-hydroxyvitamin D₃-1 α -hydroxylase by the following method.

Poly(A)⁺ RNAs derived from a rat induced with 25-hydroxyvitamin D₃-1 α -hydroxylase activity and a non-induced rat are individually subjected to agarose electrophoresis, and the poly(A)⁺ RNAs electrophoresed are then individually transferred onto each membrane filter in a conventional manner.

Using these membrane filters, Northern hybridization is carried out using the amplified DNA fragment as a probe.

By confirming that the amplified DNA fragment is hybridizable only when using the membrane filter prepared from the poly(A)⁺ RNA derived from the rat induced with the activity, it is revealed that the DNA fragment is a partial fragment of the DNA encoding 25-hydroxyvitamin D₃-1 α -hydroxylase.

The amplified DNA fragment is then inserted into a plasmid, and the resulting plasmid can be used for nucleotide sequencing and the assay of expression specificity.

The method for inserting the fragment into a plasmid includes a method for inserting the fragment into a plasmid, comprising extracting the amplified DNA fragment from the agarose using a DNA purification kit (manufactured by Bio

Rad Co.) and ligating the fragment with a vector pCRII (manufactured by Invitrogen, Co.).

4) Selection of a clone carrying DNA encoding 25-hydroxyvitamin D₃-1 α -hydroxylase

5 A cDNA library is screened by labeling the amplified DNA fragment and subjecting the resulting fragment to colony- or plaque hybridization in a conventional manner.

The labeling of the amplified DNA fragment can be carried out using for example DIG labeling kit (#1 175 033, manufactured by Boehringer Mannheim, Co.). More specifically, a DIG-labeled amplified DNA fragment can be recovered by PCR using the amplified DNA fragment as a template and utilizing the kit.

10 The plaque hybridization method includes for example the following method.

The cDNA library (phage) prepared in 1) above is spread on an agar culture medium and cultivated to a final concentration of 10,000 to 20,000 plaques per one petri dish.

Hybond N⁺ membrane (manufactured by Amersham, Co.) is placed on the petri dish with plaques formed thereon to transfer the plaque DNA onto the membrane.

15 The transfer membrane is subject to alkali treatment (comprising for example immersing the membrane in 1.5 M NaCl, 0.5M NaOH solution) and SDS treatment (comprising for example immersing in 2 x SSC, 0.1 % SDS solution), rinsing and drying, and the resulting membrane is used for hybridization as a blotted membrane with the plaque DNA immobilized thereon.

20 The blotted membrane is immersed in a hybridization solution [5 x SSC, 0.1 % Sarkosyl, 0.02 % SDS, 1 % blocking reagent for hybridization (manufactured by Boehringer Mannheim, Co.)] for 5 hours, and the labeled amplified DNA fragment which has been subjected to thermal treatment is added thereto for hybridization.

After hybridization, the membrane is subject to rinsing [for example, rinsing twice in 2 x SSC and 0.1 % SDS at room temperature for 5 minutes, and rinsing twice in 0.1 x SSC and 0.1 % SDS at 60 °C for 15 minutes] and blocking (for example, blocking in 1 x blocking solution (manufactured Boehringer Mannheim Co.), 0.1 M maleic acid, 0.15 M NaCl, pH 7.5], and thereafter, the labeled amplified DNA is detected by a variable method, depending on the labeling 25 mode of the labeled amplified DNA fragment, whereby an objective clone can be selected.

When a DNA fragment labeled with DIG is used, for example, reaction with anti-DIG antibody labeled with AP and subsequent alkali treatment [for example, immersing in 0.1 M Tris-HCl (pH 9.5), 0.1 M NaCl and 50 mM MgCl₂ solution] are carried out, and a plaque hybridized with the probe is screened on an X-ray film using a DIG luminescence detection 30 kit (#1 363 514, manufactured by Boehringer Mannheim, Co.) to select a clone containing DNA encoding 25-hydroxyvitamin D₃-1 α -hydroxylase.

5) Recovery of DNA encoding 25-hydroxyvitamin D₃-1 α -hydroxylase

35 From the clone recovered by the screening procedure described above in 4), DNA is isolated in a conventional manner to recover DNA encoding 25-hydroxyvitamin D₃-1 α -hydroxylase.

DNA nucleotide sequencing can be done by common nucleotide sequencing methods, for example, the dideoxy method by Sanger et. al. [Proc. Natl. Acad. Sci. USA, 74, 5463 (1977)] or by sequencing by using a nucleotide sequencer such as 373A - DNA sequencer [manufactured by Perkin Elmer, Co.).

40 As the gene sequence of 25-hydroxyvitamin D₃-1 α -hydroxylase thus determined includes DNA comprising the sequence represented by SEQ ID NO.3 or 5.

Based on the DNA sequence thus determined by the method, an objective DNA may be prepared by chemical synthesis with a DNA sequencer. Such DNA sequencer includes a DNA sequencer based on the thiophosphite method, manufactured by Shimadzu, and a DNA sequencer Model 1392 based on the phosphoramidites method, manufactured 45 by Perkin Elmer, Co.

The rat-derived 25-hydroxyvitamin D₃-1 α -hydroxylase gene as recovered above can be used to recover 25-hydroxyvitamin D₃-1 α -hydroxylase gene derived from other animals, for example, humans, by the following method.

50 The DNA encoding 25-hydroxyvitamin D₃-1 α -hydroxylase as recovered above is labeled with α -³²P-dCTP by using for example Megaprime DNA labeling kit (manufactured by Amersham Co.). In the same manner as for the method described above in 1), a cDNA library is prepared from objective animal tissues, for example human kidney.

The cDNA library is screened by colony- or plaque hybridization using the labeled DNA fragment described in 4) above as a probe.

From the clone recovered through the screening, the objective DNA is isolated by the method as described in 5) above, and the nucleotide sequence is determined.

55 The nucleotide sequence having high homology to the nucleotide sequence of the gene of rat 25-hydroxyvitamin D₃-1 α -hydroxylase is defined as DNA encoding 25-hydroxyvitamin D₃-1 α -hydroxylase derived from the objective animal.

The gene includes for example human kidney-derived DNA comprising the sequence represented by SEQ ID NO.

4 or 6.

6) Production of 25-hydroxyvitamin D₃-1 α -hydroxylase polypeptide

5 To express the DNA encoding 25-hydroxyvitamin D₃-1 α -hydroxylase as recovered in 5) above in a host cell, the methods described in Molecular Cloning, 2nd edition and Current Protocols in Molecular Biology, Supplement 1 to 34 and the like may be used.

10 More specifically, DNA recovered in 5) is modified into DNA fragments with appropriate lengths so that the DNA encoding 25-hydroxyvitamin D₃-1 α -hydroxylase might be contained therein, by using restriction enzymes or DNases, which are then inserted into the downstream of a promoter in an expression vector, and then, the expression vector with the DNA inserted therein is introduced into a host cell appropriate for the expression vector.

Any host cell capable of expressing the objective gene may be used, including for example bacteria, yeast, animal cells and insect cells.

15 As the expression vector, a vector, which is autonomously replicable in the host cell or possibly inserted into the chromosome and contains a promoter at the site on which the gene of 25-hydroxyvitamin D₃-1 α -hydroxylase can be transcribed, may be used.

When procaryotic cells such as bacteria are used as such host cells, it is preferable that an expression vector of 25-hydroxyvitamin D₃-1 α -hydroxylase gene is autonomously replicable in the procaryotic cells and the vector is composed of a promoter, a ribosome binding sequence, DNA encoding 25-hydroxyvitamin D₃-1 α -hydroxylase and a transcription termination sequence. A gene regulating the promoter may be contained in the vector.

20 Such expression vector includes for example pBTrp2, pBTac1, pSTac2 (all commercially available from Boehringer Mannheim, Co.), pKK2-2 (manufactured by Pharmacia, Co.) pSE280 (manufactured by Invitrogen, Co.), pGEMEX-1 (manufactured by Promega, Co.), pQE-8 (manufactured by QIAGEN, Co.), pKYP10 (Japanese Published Unexamined Patent Application No.110600/1983), pKYP200 [Agric. Biol. Chem., 48, 669 (1984)], pLSA1 [Agric. Biol. Chem., 53, 277 (1989)], pGEL1 [Proc. Natl. Acad. Sci., USA 82, 4306 (1985)], pBluescript (STRATAGENE, Co.), pTrs30 (FERM BP-5407), pTrs32 (FERM BP-5408), pGHA2 (FERM BP-400), pGKA2 (FERM BP-6798), pTerm2 (Japanese Published Unexamined Patent Application No.22979/1991, US4686191, US4939094, US5160735), pKK233-2 (manufactured by Pharmacia, Co.), pGEX (manufactured by Pharmacia, Co.), pET system (manufactured by Novagen, Co.) pSupex, pUB110, pTP5, and pC194 and the like.

30 Any promoter which can be expressed in host cells such as *Escherichia coli* may be used, including for example promoters derived from *Escherichia coli* and phages, for example *trp* promoter (P_{trp}), *lac* promoter (P_{lac}), P_L promoter, P_R promoter, P_{leu} promoter, and P_{SE} promoter; SPO1 promoter, SPO2 promoter, penP promoter and the like. Additionally, artificially designed and modified promoters, such as a promoter of two P_{trp}'s in series (P_{trp} x 2) and *lac* promoter may be used.

35 Any ribosome binding sequence may be used, as long as the sequence may be expressed in host cells such as *Escherichia coli*. Preferably, a plasmid wherein the distance between the Shine-Dalgarno sequence and the initiation codon is adjusted to an appropriate distance (for example, 6 to 18 nucleotides) may be used.

To express 25-hydroxyvitamin D₃-1 α -hydroxylase gene of the present invention, a transcription termination sequence is not necessarily required, but preferably, a transcription termination sequence is arranged immediately below the structural gene.

40 Examples of the host cell include microorganisms belonging to the genus *Escherichia*, *Serratia*, *Bacillus*, *Brevibacterium*, *Corynebacterium*, *Microbacterium*, *Pseudomonas*, and the like. Specific examples include *Escherichia coli* XL1-Blue, *Escherichia coli* XL2-Blue, *Escherichia coli* DH1, *Escherichia coli* MC1000, *Escherichia coli* KY3276, *Escherichia coli* W1485, *Escherichia coli* JM109, *Escherichia coli* HB101, *Escherichia coli* No. 49, *Escherichia coli* W3110, *Escherichia coli* NY49, *Serratia ficaria*, *Serratia fonticola*, *Serratia liquefaciens*, *Serratia marcescens*, *Bacillus subtilis*, *Bacillus amyloliquefaciens*, *Brevibacterium ammoniagenes*, *Brevibacterium immariophilum* ATCC 14068, *Brevibacterium saccharolyticum* ATCC 14066, *Corynebacterium glutamicum* ATCC 13032, *Corynebacterium glutamicum* ATCC 14067, *Corynebacterium glutamicum* ATCC 13869, *Corynebacterium acetoacidophilum* ATCC 13870, *Microbacterium ammoniaphilum* ATCC 15354, *Pseudomonas* sp. D-0110 and the like.

50 As the method for introducing the recombinant vectors, any method for introducing DNA into the host cells may be used, including for example a method comprising the use of calcium ion [Proc. Natl. Acad. Sci. USA, 69, 2110 (1972)], protoplast method (Japanese Published Unexamined Patent Application No.2483942/1988), and methods described in Gene, 17, 107 (1982) and Molecular & General Genetics, 168, 111 (1979).

In case of using yeast strains as host cells, expression vectors for example YEp13 (ATCC 37115), YEp24 (ATCC 37051), YCp50 (ATCC 37419), pHS19, and pHS15 may be used.

55 As the promoter, any promoter which can be expressed in yeast strains may be used. For example, promoters such as PHO5 promoter, PGK promoter, GAP promoter, ADH promoter, gal 1 promoter, gal 10 promoter, heat shock protein promoter, MF α 1 promoter, CUP 1 promoter and the like may be listed.

Host cells used include for example *Saccharomyces cerevisiae*, *Shizosaccharomyces pombe*, *Kluyveromyces fragilis*, *Trichosporon pullulans*, and *Schwanniomyces alluvius*.

As the method for introducing the recombinant vectors, any method for introducing DNA into yeast cells may be used, for example, electroporation method [Methods. Enzymol., 194, 182 (1990)], spheroplast method [Proc. Natl. Acad. Sci. USA, 84, 1929 (1978)], lithium acetate method [Journal of Bacteriology, 153, 163 (1983)], a method described in Proc. Natl. Acad. Sci. USA, 75, 1929 (1978) and the like.

In case of using animal cells as a host, the expression vector includes for example pcDNA1, pcDM8 (commercially available from Funakoshi, Co.), pAGE107 (Japanese Published Unexamined Patent Application No.22979/1991; Cytotechnology, 3, 133 (1990)), pAS3-3 (Japanese Published Unexamined Patent Application No.227075/1990), pCDM8 [Nature, 329, 840 (1987)], pcDNA1/Amp (manufactured by Invitrogen, Co.), pREP4 (manufactured by Invitrogen, Co.), pAGE103 [J. Biochem., 101, 1307 (1987)], and pAGE210.

As a promoter, any promoter which can be expressed in animal cells may be used, including for example a promoter of IE (immediate early) gene of cytomegalovirus (human CMV), an early promoter of SV40 or a promoter of metallothionein, a promoter retrovirus, a heat shock promoter and an SR α promoter. Additionally, the enhancer of the IE gene of human CMV may be used in combination with such promoter.

Examples of the host cell include Namalwa cell, monkey cos cell, Chinese hamster CHO cell, HST5637 (Japanese Published Unexamined Patent Application No.299/1988) and the like.

As the method for introducing recombinant vector into animal cells, any method for introducing DNA into animal cells may be used, e.g., electroporation method [Cytotechnology, 3, 133 (1990)], calcium phosphate method [Japanese Published Unexamined Patent Application No.227075/1990], lipofection method [Proc. Natl. Acad. Sci., USA, 84, 7413 (1987)] and the method described in Virology, 52, 456 (1973)]. The preparation of a transformant and cultivation of the transformant may be carried out according to the method described in Japanese Published Unexamined Patent Application No.227075/1990 or Japanese Published Unexamined Patent Application No.257891/1990.

In case of using insect cells as a host, the protein may be expressed according to the methods described in Baculovirus Expression Vectors, A Laboratory Manual, W. H. Freeman and Company, New York, 1992; Current Protocols in Molecular Biology, Supplement 1-38(1987-1997); Bio/Technology, 6, 47 (1988) and the like.

More specifically, the protein can be expressed by co-introduction of the transfer vector containing interest gene and helper DNA fragment of baculovirus into an insect cell to recover a recombinant virus in the supernatant of the culture of the insect cell and infecting an insect cell with the recombinant virus.

The transfer vector for gene introduction to be used in the method includes for example pVL1392, pVL1393, pBlue-BacIII (all manufactured by Invitrogen, Co.) and the like.

As the helper DNA fragment of baculovirus, for example, Autographa californica nuclear polyhedrosis virus, which is a virus infecting insects of the family Barathra, may be used.

As such insect cell, *Spodoptera frugiperda* oocytes Sf9 and Sf21 [Baculovirus Expression Vectors, A Laboratory Manual, W. H. Freeman and Company, New York, 1992], *Trichoplusia ni* oocytes High 5 (manufactured by Invitrogen Co.) and the like, may be used.

The method for co-introducing the above-described transfer vector containing interest gene and the helper DNA fragment of baculovirus into insect cells to prepare the recombinant virus includes for example calcium phosphate method (Japanese Published Unexamined Patent Application No.227075/1990), lipofection method [Proc. Natl. Acad. Sci. USA, 84, 7413 (1987)], and the like.

As the expression method of the gene, secretory production and expression of fused protein may be carried out according to the method described in Molecular Cloning, 2-nd edition and the like, in addition to direct expression.

When the gene is expressed in yeast, animal cells or insect cells, a glycosylated protein can be obtained.

The transformant thus obtained is cultivated in a culture medium to form polypeptide of the present invention in the culture, and the formed polypeptide is recovered from the culture, whereby the polypeptide of the present invention can be produced. The transformant of the present invention is cultivated in a culture medium according to a conventional method for use in cultivating hosts.

As the culture medium to cultivate a transformant recovered by using procaryotic organisms such as *Escherichia coli* or eucaryotic organisms such as yeast, any natural culture medium or any synthetic culture medium may be used, so long as it contains carbon sources, nitrogen sources, inorganic salts and the like which can be assimilated by the organisms.

Any carbon source which can be assimilated by the organisms may be used, including carbohydrates such as glucose, fructose, sucrose, molasses containing them, starch and starch hydrolysates; organic acids such as acetic acid and propionic acid; alcohols such as ethanol and propanol.

As such nitrogen sources, ammonia; ammonium salts of inorganic acids or organic salts, such as ammonium chloride, ammonium sulfate, ammonium acetate, and ammonium phosphate; other nitrogen containing compounds; peptone; meat extract; yeast extract; corn steep liquor; case in hydrolysates; soy bean meal; soy bean meal hydrolysates; various fermentation products, and digested products thereof, may be used.

As the inorganic substances, potassium dihydrogen phosphate, dipotassium hydrogen phosphate, magnesium phosphate, magnesium sulfate, sodium chloride, ferrous sulfate, manganese sulfate, copper sulfate, calcium carbonate and the like, may be used.

Cultivation is generally carried out under aerobic conditions, for example, by shaking culture or spinner culture under aeration. The cultivation is carried out at 15 to 40 °C for 16 hours to seven days at pH 3.0 to 9.0. The pH is adjusted with an inorganic or organic acid, an alkali solution, urea, calcium carbonate, ammonia and the like.

During cultivation, antibiotics such as ampicillin and tetracycline may be added to the culture medium, if necessary.

For cultivating microorganisms transformed with an expression vector prepared using an inducible promoter, an inducer may be added to the culture medium, if necessary. For cultivating microorganisms transformed with an expression vector prepared using *lac* promoter, for example, isopropyl- β -D-thiogalactopyranoside may be added to the medium; for cultivating microorganisms transformed with an expression vector prepared using *trp* promoter, for example, indole acrylic acid may be added to the medium.

As the culture medium for cultivating a transformant recovered by using animal cells as the hosts, RPMI 1640 culture medium [The Journal of the American Medical Association, 199, 519 (1967)], Eagle's MEM culture medium [Science, 122, 501 (1952)], Dulbecco's modified MEM culture medium [Virology, 8, 396 (1959)], DMEM culture medium (manufactured by GIBCO BRL, Co.), 199 culture medium [Proceedings of the Society for the Biological Medicine, 73, 1 (1950)] for conventional use or culture media prepared by adding fetal calf serum and the like to these culture media, may be used.

Generally, cultivation is carried out in the presence of 5% CO₂ at pH 6 to 8 at 30 to 40 °C for 1 to 7 days.

During cultivation, if necessary, antibiotics such as kanamycin and penicillin may be added to the culture medium.

As the culture medium to cultivate transformants recovered using insect cells as the hosts, culture medium for general use, such as TNM-FH culture medium [manufactured by Pharmingen, Co.], Sf-900 II SFM culture medium [manufactured by Life Technologies, Co.], ExCell 400, ExCell 405 [both manufactured by JRH Biosciences, Co.], Grace's Insect Medium [Grace, T.C.C., Nature, 195, 788 (1962)] and the like, may be used.

Cultivation is carried out at pH 6 to 7 at 25 to 30 °C for 1 to 5 days.

During cultivation, if necessary, antibiotics such as gentamycin may be added to the culture medium.

To isolate and purify the polypeptide expressed by the method described above from the culture of the transformant, conventional isolation and purification methods of enzymes may be used.

When the polypeptide of the present invention is expressed in cells at its dissolved state, a purified sample of the polypeptide is obtained as follows. The cells are recovered through centrifugation after the cultivation, suspended in an aqueous buffer, and disrupted by means of ultrasonic oscillator, French Press, Manton Gaulin homogenizer, Dismill and the like, to recover a cell-free extract. From the supernatant recovered by the centrifugation of the cell-free extract, a purified sample can be recovered by conventional isolation and purification methods of enzymes, singly or in combination, such as solvent extraction method, salting out methods with ammonium sulfate, etc., desalting method, precipitation methods with organic solvents, anion exchange chromatography by means of resins such as diethylaminoethyl (DEAE)-Sephadex, DIAION HPA-75 (manufactured by Mitsubishi Chemical Corporation); cation exchange chromatography by means of resins such as S-Sepharose FF (manufactured by Pharmacia, Co.); hydrophobic chromatography using resins such as butyl Sepharose and phenyl Sepharose; gel filtration methods using molecular sieves; affinity chromatography method; chromatofocusing method; electrophoresis methods such as isoelectric focusing; and the like.

When the polypeptide is expressed in cells in the form of an inclusion body, a purified sample of the polypeptide is obtained as follows. The cells are similarly recovered, disrupted, and centrifuged to recover a precipitation fraction, from which the polypeptide is recovered according to a conventional method, and the inclusion body of the polypeptide is solubilized with a polypeptide denaturant. The solubilized solution is diluted or dialyzed in a dilute solution at such an extent that the resulting solution does not contain any polypeptide denaturant or the polypeptide is not any more denatured at the concentration of the polypeptide denaturant, to renature the polypeptide into a normal steric configuration, from which a purified sample can be recovered according to the same isolation and purification method as described above.

In case that the polypeptide of the present invention or derivatives thereof such as a sugar modified product thereof are secreted extracellularly, the polypeptide or the derivatives thereof can be recovered from the culture supernatant. More specifically, the culture is treated by the method as described above, such as centrifugation, to recover a soluble fraction, and from the fraction, a purified sample is recovered using the isolation and purification method as described above.

Additionally, the polypeptide expressed by the above method may be prepared by chemical synthetic methods such as Fmoc method (fluorenylmethyloxycarbonyl method), tBoc method (t-butyloxycarbonyl method) and the like. Alternatively, the polypeptide can be prepared by utilizing peptide synthesizers commercially available from Sowa Trade (manufactured by Advanced chemTech, Co., USA), Perkin-Elmer Japan (manufactured by Perkin-Elmer, Co., USA), Pharmacia Biotech (manufactured by Pharmacia Biotech, Co., Sweden), Aroka (manufactured by Protein Technology

Instrument, Co., USA), KURABO (manufactured by Synthecell-Vega, Co., USA), Japan PerSeptive Limited (manufactured by PerSeptive, Co., USA), Shimadzu, Co. and the like.

7) Production of 1 α , 25-dihydroxyvitamin D₃

The polypeptide having 25-hydroxyvitamin D₃-1 α -hydroxylase and 25-hydroxyvitamin D₃ are put in an aqueous medium to form 1 α , 25-dihydroxyvitamin D₃ in the aqueous medium, and the formed 1 α , 25-dihydroxyvitamin D₃ is recovered from the aqueous medium. Thus, 1 α , 25-dihydroxyvitamin D₃ can be produced.

As a polypeptide having 25-hydroxyvitamin D₃-1 α -hydroxylase activity, the polypeptide purified by the method described above in 6) and the microbial culture obtained by the method described above in 6) or a treated product of the culture obtained by treating the culture in various ways and the like, may be used.

Examples of the treated product of the culture broth include a concentrated product of the culture, a dried product of the culture, a culture supernatant obtained by centrifuging the culture, a concentrated product of the culture supernatant, an enzyme preparation obtained from the culture supernatant, cells (including microbial cells) obtained by centrifuging the culture, a dried product of the cells, a freeze-dried product of the cells, a surfactant-treated product of the cells, an ultrasonic-treated product of the cells, a mechanically disrupted product of the cells, a solvent-treated product of the cells, an enzyme-treated product of the cells, a protein fraction of the cells (fractions having 25-hydroxyvitamin D₃-1 α -hydroxylase activity), an immobilized product of the cells and an enzyme preparation obtained by extraction from the cells.

The concentration of the polypeptide having 25-hydroxyvitamin D₃-1 α -hydroxylase activity is 0.01 to 50 g/l, preferably 0.05 to 10 g/l, as wet cells.

The aqueous medium includes water, buffers such as phosphate salts, carbonate salts, acetate salts, borate salts, citrate salts, and Tris; and aqueous solutions containing organic solvents such as alcohols such as methanol and ethanol; esters such as ethyl acetate; ketones such as acetone; amides such as acetoamide. If necessary, surfactants such as Triton X-100 (manufactured by Nakarai Tesque, Co.) and Nonion HS204 (manufactured by Nippon Oils and Fats Co.), or organic solvents such as toluene and xylene may be added at about 0.1 to 20 g/l.

The concentration of 25-hydroxyvitamin D₃ is 0.01 to 50 g/l, preferably 0.01 to 10 g/l.

1 α , 25-dihydroxyvitamin D₃ can be produced by adding polypeptide having 25-hydroxyvitamin D₃-1 α -hydroxylase activity and 25-hydroxyvitamin D₃. The reaction is carried out at 15 to 80 °C, preferably 20 to 40 °C, at pH 3 to 11, preferably pH 4 to 9, for 5 minutes to 96 hours.

8) Preparation of an antibody recognizing 25-hydroxyvitamin D₃-1 α -hydroxylase

A purified product of the whole length or a partial fragment of the protein obtained by the method described in the above in 6) or a peptide having a partial amino acid sequence of the protein of the present invention is used as the antigen. The antigen is administered to animal by subcutaneous, intravenous or intraperitoneal injection together with an appropriate adjuvant (for example, complete Freund's adjuvant, aluminum hydroxide gel, pertussis vaccine, or the like).

Examples of the animals used include rabbits, goats, 3- to 20-week-old rats, mice, hamsters and the like.

Preferable dosage of antigen is 50 to 100 μ g per animal.

When a peptide is used as the antigen, it is preferred to use the peptide as the antigen after binding it covalently to a carrier protein, such as keyhole limpet haemocyanin, bovine thyroglobulin or the like. The peptide used as the antigen can be synthesized using a peptide synthesizer.

Administration of the antigen is carried out 3 to 10 times at one- to two-week intervals after the first administration. A blood sample is recovered from the fundus of the eye 3 to 7 days after each administration, and the serum is tested, for example, by enzyme immunoassay (Enzyme-linked Immunosorbent Assay (ELISA), published by Igaku Shoin (1976); Antibodies - A Laboratory Manual, Cold Spring Harbor Laboratory (1988)) as to whether it is reactive with the antigen used for immunization. A non-human mammal whose serums shows a sufficient antibody titer against the antigen used for immunization is submitted for use as the supply source of serum or antibody producing cells.

A polyclonal antibody can be prepared by isolating and purifying it from the serum.

A monoclonal antibody can be prepared by preparing a hybridoma through fusion of the antibody producing cells with myeloma cells of a non-human mammal and culturing the hybridoma, or administering the hybridoma to an animal to induce ascites tumor in the animal, and then isolating and purifying it from the culture medium or ascitic fluid.

Examples of the antibody producing cells include spleen cells, lymph nodes and antibody producing cells in peripheral blood. Particularly, spleen cells are preferred.

Examples of the myeloma cells include cell lines derived from mouse, such as P3-X63Ag8-U1 (P3-U1) cell line [Current Topics in Microbiology and Immunology, 18, 1-7 (1978)], P3-NS1/1-Ag41 (NS-1) cell line [European J. Immunology, 6, 511-519 (1976)], SP2/O-Ag14 (SP-2) cell line [Nature, 276, 269-270 (1978)], P3-X63-Ag8653 (653) cell line [J. Immunology, 123, 1548-1550 (1979)], P3-X63-Ag8 (X63) cell line [Nature, 256, 495-497 (1975)] and the like, which are

8-azaguanine-resistant mouse (BALB/c) myeloma cell lines.

Hybridoma cells can be prepared in the following manner.

Antibody producing cells and myeloma cells are fused, suspended in HAT medium (normal medium supplemented with hypoxanthine, thymidine and aminopterin) and then cultured for 7 to 14 days. After the culturing, a portion of the culture supernatant is sampled and tested, for example, by enzyme immunoassay to select those which can react with the antigen but not with protein which does not contain the antigen. Thereafter, cloning is carried out by limiting dilution analysis, and a hybridoma which shows stable and high antibody titer by enzyme immunoassay is selected as monoclonal antibody producing hybridoma cells.

With regard to the method for the isolation and purification of the polyclonal antibody or monoclonal antibody, centrifugation, ammonium sulfate precipitation, caprylic acid precipitation, or chromatography using a DEAE-Sephacel column, an anion exchange column, a protein A or G column, a gel filtration column and the like may be employed alone or as a combination thereof.

9) Utilization of the polypeptide and the DNA encoding the polypeptide of the present invention and the antibody recognizing the polypeptide of the present invention

(1) The polypeptide of the present invention can be utilized for producing 1α , 25-dihydroxyvitamin D_3 as active type vitamin D_3 .

(2) The whole length or partial fragments of the polypeptide of the present invention can be utilized as an antigen against the antibody recognizing 25-hydroxyvitamin D_3 - 1α -hydroxylase.

(3) By administering the whole length of the 25-hydroxyvitamin D_3 - 1α -hydroxylase or partial fragments thereof having the activity into biological organisms, diseases due to the decrease of the enzyme protein, such as osteoporosis, can be treated therapeutically.

(4) By using the DNA of the present invention, the mRNA of 25-hydroxyvitamin D_3 - 1α -hydroxylase gene can be detected by Northern hybridization method (Molecular Cloning, 2-nd edition), PCR method [PCR Protocols, Academic Press (1990)], and RT-PCR method and the like.

The diagnostic method for assaying the expression level of the mRNA of the gene of 25-hydroxyvitamin D_3 - 1α -hydroxylase by utilizing the detection method, is useful for suppressing the onset of adult diseases such as osteoporosis induced by the decrease of active type vitamin D_3 and is also effective for early diagnosis of genetic diseases due to congenital deficiency of the 25-hydroxyvitamin D_3 - 1α -hydroxylase gene.

According to Northern hybridization method, the expression level of mRNA is assayed on the basis of the label of a probe hybridized, for example, on the basis of the radioactivity in case of labeling with for example ^{32}P or the fluorescence in case of fluorescent labeling. The expression level of mRNA is assayed, on the basis of the fluorescence of a DNA specific fluorescent dye, for example ethidium bromide and Cyber Green 1 which is used for staining amplified fragments.

(5) The DNA of the present invention is inserted into virus vectors such as retrovirus and adenovirus and other vectors, and the resulting DNA can be used for therapeutic treatment according to gene therapy.

(6) By using the anti-25-hydroxyvitamin D_3 - 1α -hydroxylase antibody of the present invention, 25-hydroxyvitamin D_3 - 1α -hydroxylase can be detected and assayed in samples of blood, some organs, cells and the like. Specifically preferable methods therefor include ELISA method by using microtiter plates, fluorescent antibody methods, Western blot method and the like; additionally, immuno-histological staining by using pathological sections may also be utilized. Thus, the antibody of the present invention is useful for the diagnosis of diseases such as osteoporosis, due to the decrease of the expression of vitamin D_3 - 1α -hydroxylase, the diagnosis of the onset thereof and early prediction of the possibility of the onset thereof and the like. Similarly, the antibody is also useful as a laboratory reagent for research works for the protein.

(7) By using the antibody of the present invention, polypeptides having 25-hydroxyvitamin D_3 - 1α -hydroxylase activity are immuno-histologically stained, and thus, an immuno-histological staining agent containing the antibody can be provided.

(8) By using the DNA of the present invention and through the hybridization thereof with the genome DNA, the DNA in the promoter region of the gene can be cloned. By using DNA fragments in the promoter region, molecules involved in the regulation of the expression of the gene can be screened and analyzed.

The examples illustrate the invention.

When kits were used in individual procedures, experiments were progressed according to the protocols attached to the kits, unless otherwise stated specifically. Fundamental genetic manipulation techniques were according to Molecular Cloning, 2-nd edition.

Example 1Preparation of kidney from rats fed with vitamin D₃ deficient diet

- 5 Immediately after weaning, four male SD rats were given vitamin D₃ deficient diet for 3 weeks (age 6 weeks).
 DIET 11 [Suda, et. al., J. Nutrition, 100, 1049 (1970); commercially available as Purified diet for Rat from Teklad Co, Madison, WI, USA] was used as the vitamin D₃ deficient diet. The diet was vitamin D deficient and low calcium diet at a calcium content of 0.03 % and a phosphate content of 0.6 %.
- Deionized water was used for supplementing the rats with water.
- 10 48 hours prior to sacrifice, 1 α , 25-dihydroxyvitamin D₃ (manufactured by Calbiochem, Co., CA, USA) was intravenously injected at 1 μ g/rat into the rats.
- After the designed dieting term was terminated, the rats were anesthetized with ether. From the abdominal aortas of the rats, blood was drawn out, and then, the rats were sacrificed to death by phlebotomy and immediately thereafter, the rats were autopsied to resect the kidneys.
- 15 The kidneys were rinsed in PBS [containing NaCl (8 g), KCl (0.2 g), NaH₂PO₄ · 12H₂O (2.9 g) and KH₂PO₄ (0.2 g) per one liter), and the resulting kidneys were frozen in liquid nitrogen.
- As a control group, rats were given normal diet (Rat diet containing calcium (0.5 g), phosphate (0.6 g) and vitamin D₃ (200 IU) per 100 g) in a similar fashion, and then, the kidneys were prepared by the same method as described above. The resulting kidneys were used as kidneys from rats with no activity induction.

20

Example 2Preparation of mRNA from rat kidneys

- 25 The kidneys prepared from the rats fed with the vitamin D₃ deficient diet and the kidneys derived from the rats fed with normal diet, weighed 0.78 g and 0.94 g, respectively, were rinsed in PBS and were then frozen in liquid nitrogen. The frozen kidneys can be stored at -80 °C.
- The frozen kidneys were cut into pieces in liquid nitrogen with a wearing blender, until the tissues were hashed into sand size form. Then, the liquid nitrogen was evaporated.
- 30 The sand-like tissues were homogenized in ice cooling with a homogenizer (Digital Homogenizer; manufactured by Inouchi, Co.), while adding thereto 35 ml of 5.5 M GTC solution (containing 324.5 g of guanidine isothiocyanate, 3.7 g of sodium citrate, and 3.3 g of Sarkosyl in 500 ml) and 492 μ l of 2-mercaptoethanol, and the homogenate in suspension was passed four times through an injection needle of gauge 18 arranged on a 50-ml injection cylinder.
- The suspension was then transferred into a 15-ml centrifuge tube, for centrifugation at 6,000 rpm at 20 °C for 10
- 35 minutes, to recover the supernatant.
- The supernatant was then overlaid in 16-ml portions on a CsTFA preparative solution [a mixture solution of CsTFA solution (100 ml) manufactured by Pharmacia, Co., 82.06 ml of 0.25 M EDTA solution (pH 7.0), and 23.09 ml of H₂O] in a 40-ml polyallomer tube for ultracentrifugation, and the tube was then ultra-centrifuged under conditions of 25,000 rpm and 18 °C for 25 hours.
- 40 After discarding the supernatant, the tube was cut at the position of about 1.5 cm from the bottom of the tube, and the resulting precipitate was dissolved in 0.6 ml of 4M GTC solution [a mixture solution of 5.5M GTC solution (4 ml), 1.5 ml of H₂O, and 56 μ l of 2-mercaptoethanol].
- The dissolved solution was centrifuged at 14,000 rpm for 15 seconds, to recover the supernatant.
- After adding 15 μ l of 1M sodium acetate and 0.45 ml of ethanol to the supernatant and thereby suspending the pre-
- 45 cipitate, the resulting suspension was centrifuged to recover the precipitate.
- The precipitate was rinsed in 70 % ethanol, suspended in 1 ml of TE buffer [10 mM Tris-HCl (pH 8.0), 1 mM EDTA-NaOH (pH 8.0)], and centrifuged at 14,000 rpm for 15 seconds, to recover the supernatant.
- Adding a 2.5-fold volume of 70% ethanol to the supernatant, followed by centrifugation, the resulting precipitate was recovered.
- 50 The precipitate was rinsed in 70 % ethanol and was then dissolved in 500 μ l of TE buffer.
- Through the procedure, the whole RNA was recovered from the kidneys from the rats with activity induction and the rats with no activity induction, which was calculated as 639 μ g and 918 μ g, respectively, on the basis of the absorbance at 260 nm.
- The whole RNA solution (150 μ l) derived from the rats with activity induction was effected with thermal treatment
- 55 at 65 °C for 5 minutes, which was immediately cooled in ice.
- To the solution were added 0.5 ml of 5M NaCl and 0.15 g oligo dT cellulose (manufactured by Collaborative Research, Co., Type 3) equilibrated with TE/NaCl [10 mM Tris-HCl (pH 7.5), 500 mM NaCl], to adsorb the whole RNA onto the cellulose.

The cellulose was packed in a column, through which the TE/NaCl solution was passed for washing the column, followed by elution of mRNA with TE solution of 0.5 ml, to fractionate and collect the eluate in 200 µl-fractions. From the individual fractionated solutions, 2 µl portions

5 were sampled, followed by addition of 1 µg/ml ethidium bromide (20 µl), to detect luminescent sampled solutions under ultraviolet irradiation.

Ethanol was added to the fractionated solutions corresponding to the luminescent sampled solutions, to recover precipitates.

The precipitates were rinsed in 80 % ethanol and suspended in TE buffer.

Through the procedures, mRNA of 14.3 µg was recovered from the kidneys of the rats with activity induction.

10

Example 3

Preparation of cDNA library

15 By using ZAP-cDNA synthesis kit (#200400) manufactured by Stratagene Co., a cDNA library was constructed according to the instruction manual attached to the kit.

By using 4 µg of mRNA derived from the rats with activity induction as prepared in Example 2, first strand DNA was synthesized through reverse-transcriptase reaction, and after RNase reaction, second strand DNA was synthesized with DNA polymerase I.

20 Under high temperature conditions, PfuDNA polymerase reaction was effected to make the termini of the cDNA to blunt end.

By ligating an *EcoRI* adapter fragment to the cDNA for phosphorylation and digesting the resulting cDNA with *XhoI*, a cDNA fragment with *EcoRI-XhoI* cleavage sites on both the termini was prepared.

25 The cDNA fragment was inserted into the *EcoRI-XhoI* site of λ ZAP II, and by subsequent packaging with Giga pace Gold Packaging Kit (manufactured by Stratagene, Co.) and infection by using *Escherichia coli* host XL1-Blue, MRF strain and helper phage VCS257, a cDNA library was constructed.

Example 4

30 Selection of a clone harbouring mRNA molecule specifically expressed in the kidneys of the rats with induced activity

The amino acid sequences of the rat-derived hydroxylase of the position 25 of vitamin D₃ and the hydroxylase of the position 24 thereof were previously reported, and among the regions well preserved in these vitamin D₃ hydroxylases of the family P450, the partial amino acid sequences of the adrenodoxin binding region (region A) essential for the enzyme activity and of the hem binding region (region H) were selected, and on the basis of the DNA sequences 35 were designed a sense primer and an antisense primer for PCR amplification of the gene in the regions.

More specifically, DNA comprising the nucleotide sequence represented by SEQ ID No.7 corresponding to the region A was used as the sense primer; and DNA comprising the nucleotide sequence represented by SEQ ID NO.8 corresponding to the region H was used as the antisense primer.

40 By using the ZAP-cDNA synthesis kit (#200400) manufactured by Stratagene Co. and 4 µg of the mRNA derived from the rats having activity induction, first strand DNA was synthesized with a primer random hexamer.

By using the first strand DNA as the template, the DNA comprising the nucleotide sequence represented by SEQ ID NO.7 as the sense primer and the DNA comprising the nucleotide sequence represented by SEQ ID NO.8 as the antisense primer and by utilizing RT-PCR kit manufactured by Stratagene, Co., PCR was effected.

45 By using DNA Thermal Cycler 480 manufactured by Perkin Elmer, Co., PCR was effected at 35 cycles, each cycle composed of 94 °C for 30 seconds, 42 °C for one minute and 72 °C for one minute.

The reaction product was analyzed by agarose gel electrophoresis, and a 255-bp amplification fragment (AH fragment) was observed. By using a DNA purification kit (manufactured by Bio Rad, Co.), the fragment was extracted from agarose, which was then inserted into pCRII vector (manufactured by Invitrogen, Co.).

50 From the whole RNAs derived from the rats induced with 25-hydroxyvitamin D₃-1α-hydroxylase activity and the non-induced rats were prepared poly(A)⁺RNAs, which were then subject individually to agarose electrophoresis, to transfer the electrophoresed mRNAs onto membrane filters in a conventional manner.

By using these membrane filters, Northern hybridization was effected by using the amplified AH fragment as the probe.

55 The amplified AH fragment was hybridized only when the membrane filter prepared from the mRNA derived from the rats with activity induction was used.

The AH fragment had nucleotide sequences corresponding to the regions A and H.

By using the AH fragment and 3' RACE system kit manufactured by BRL, Co., a PCR amplified fragment containing

the 3' noncoding region of the DNA encoding the 25-hydroxyvitamin D₃-1 α -hydroxylase was recovered by the following method.

By using the Oligo dT/AUAP primer attached to the 3' RACE system kit manufactured by BRL, Co. and 4 μ g of the mRNA from the rats with activity induction as recovered in Example 2, cDNA was synthesized.

5 The cDNA was used as a template.

Based on the sequence of the AH fragment amplified above, DNA comprising the nucleotide sequence represented by SEQ ID NO.9 was synthesized and used as a sense primer.

The AUAP primer attached to the 3' RACE system kit manufactured by BRL, Co. was used as an antisense primer.

10 By using the template, the sense primer and the antisense primer, PCR was effected at 35 cycles, each cycle composed of 94 °C for one minute, 55 °C for one minute and 72 °C for 2 minutes.

The reaction product was analyzed by agarose gel electrophoresis, and an amplified fragment of 1.3 kb (A3 fragment) was observed. By using a DNA purification kit (manufactured by Bio Rad, Co.), the fragment was extracted from agarose, which was then inserted into pCRII vector.

15 In the same manner as for the AH fragment, the A3 fragment was specifically hybridized with the mRNA from the rats with activity induction.

The A3 fragment contained almost whole length of the AH fragment.

Example 5

20 Recovery of DNA encoding 25-hydroxyvitamin D₃-1 α -hydroxylase

The cDNA phage library prepared in Example 3 was spread on an agar medium and cultivated to a final concentration of 10,000 to 20,000 plaques per one petri dish.

25 HybondN⁺ membrane (manufactured by Amesham, Co.) was placed on each of the petri dishes with the plaques formed thereon, to transfer the plaque DNA onto the membrane. Two transcription membranes were prepared per one petri dish.

The transcription membranes were subject to alkali treatment (immersion in 1.5 M NaCl and 0.5 M NaOH) and SDS treatment (immersion in 2 x SSC and 0.1 % SDS solution), rinsed and dried, and then, the resulting membranes with plaque DNA immobilized thereon were used as blotting membranes for the following hybridization.

30 By using DIG labeling kit (#1 175 033; manufactured by Boehringer Mannheim, Co.) and 2 ng each of the AH fragment and A3 fragment as templates, PCR was effected, to recover DIG labeled AH fragment or A3 fragment.

PCR was effected under conditions of 30 cycles; each cycle of a process of 94 °C for one minute, 50 °C for one minute and 72 °C for one minute.

The resulting DIG labeled AH fragment and DIG labeled A3 fragment were used as the following probes.

35 The blotting membranes prepared above were immersed in a hybridization solution [5 x SSC, 0.1 % Sarkosyl, 0.02 % SDS, 1 % hybridization blocking solution (manufactured by Boehringer Mannheim, Co.)] at 60 °C for 5 hours, followed by addition of thermally treated DIG labeled probe (10 μ l/10 ml-hybridization solution), for overnight hybridization at 65 °C.

40 After hybridization, the membranes were subject to rinsing (rinsing twice in 2 x SSC and 0.1 % SDS at room temperature for 5 minutes, rinsing twice in 0.1 x SSC and 0.1 % SDS at 60 °C for 15 minutes), blocking [effected by using 1 x blocking solution (manufactured by Boehringer Mannheim, Co.), 0.1M maleic acid, 0.15M NaCl, pH 7.5], reaction with AP labeled anti-DIG antibody (effected according to the protocol by Boehringer Mannheim, Co.), and alkali treatment [0.1M Tris-HCl (pH 9.5), 0.1M NaCl and 50 mM MgCl₂], and by using thereafter DIG luminescence detection kit (#1 363 514; manufactured by Boehringer Mannheim, Co.), plaques hybridizable with the probes were screened on an

45 X-ray film.

By using firstly the DIG labeled AH fragment as the DIG labeled probe to select plaques hybridizable with the fragment and by subsequently using the DIG labeled A3 fragment, plaques hybridizable with the fragment were selected from the plaques described above.

50 The plaques selected at each stage were again inoculated on petri dishes, and then, it was confirmed that these were hybridizable. By PCR using both the primers of the region A and AUAP, additionally, it was confirmed that the plaques had the nucleotide sequence of the A3 fragment.

After screening of 35 petri dishes in total, finally, four plaques (Nos.221, 522, 411, 111) were selected.

From individual plaque clones was extracted DNA, which was then ligated to pBluescript vector by using rapid excision kit (#211204; manufactured by Stratagene, Co.), and subsequently, the nucleotide sequence of DNA inserted into the clone was analyzed by using M13 primer.

55 By the analysis with the clone No.221, DNA comprising a nucleotide sequence of 2469 bp was observed, as represented by SEQ ID No.5.

An open reading frame (referred to as ORF hereinafter) encoding 501 amino acids was observed in the DNA, in

which amino acid sequences believed as the hem binding region and adrenodoxin binding region in common with the P450 family protein were present.

Example 6

Expression of isolated 25-hydroxyvitamin D₃-1 α -hydroxylase gene in animal cells

From the clone No.221 described in Example 5 was prepared a plasmid, which was subsequently digested with HindIII and XbaI. Expression vector pcDNA3 (manufactured by Invitrogen, Co.) for animal cells was similarly digested with HindIII and XbaI.

The cleavage fragments recovered above were individually subject to agarose electrophoresis, which were thereby separated and extracted.

The resulting DNA fragments from the vector and the inserted gene fragment were ligated together, by using a DNA ligation kit(manufactured by TaKaRa Brewery), to recover a ligated plasmid.

By using the plasmid, *Escherichia coli* strain DH5 α was transformed, and thereafter, an ampicillin resistant strain was selected, from which the plasmid was extracted according to a known method.

Based on the analysis of the plasmid by restriction cleavage, it was confirmed that the plasmid inserted the objective gene. The plasmid was named pCMD3R.

By electroporation [Potter et al., Proc. Natl. Acad. Sci. USA, 81, 716 (1984)], pCMD3R was introduced into an animal cell, to be expressed therein as follows. COS7 cell was cultivated in a DMEM culture medium (manufactured by GIBCO BRL, Co.) supplemented with 10 % FCS (fetal calf serum) in a petri dish for 2 days.

After cultivation, the cells were peeled off from the petri dish by trypsin treatment, and the cells were rinsed in PBS and then suspended in 0.5 ml of KPBS (137 mM KCl, 2.7 mM NaCl, 8.1 mM Na₂HPO₄, 1.5 mM NaH₂PO₄, 4 mM MgCl₂), to a final concentration of 2 to 6.0 x 10⁶/ml.

The suspension and 15 μ g of pCMD3R plasmid were mixed together in a pulser cuvette (manufactured by BIO-RAD, Co.) with a groove width of 0.4 cm, and the resulting mixture was then applied to an electroporation system Gene pulser (manufactured by BIO-RAD, Co.) for pulse loading under conditions of 960 μ F and 0.22 kV, to introduce the DNA into the cell.

The DNA introduced cell was suspended in 10 ml of DMEM culture medium containing 10 % FCS, for cultivation in a 5 % CO₂ incubator at 37 °C for 48 to 72 hours.

By discarding the culture in the petri dish and rinsing the cell twice in PBS, the cell was scraped off with a scraper, followed by centrifugation to collect the cell.

Example 7

Recovery of human-derived 25-hydroxyvitamin D₃-1 α -hydroxylase gene

From 1.2 g of tissue resected from human kidney cancer, the whole RNA (750 μ g) was recovered according to the method described in Example 2, and 9.5 μ g of mRNA was recovered from the whole RNA.

By using 5 μ g of the mRNA, a human cDNA library was constructed by the method described in Example 3.

According to the method described in Example 5, DNA encoding the human derived 25-hydroxyvitamin D₃-1 α -hydroxylase was recovered.

The whole length of the rat vitamin D₃ hydroxylase gene of 2469 bp as isolated in Example 5 was DIG labeled according to the method described in Example 5, which was then used as a probe.

Hybridization was effected overnight in a hybridization solution containing formamide at 40 % under a condition of 42 °C.

Through the hybridization, four clones were selected.

According to the method described in Example 5, DNA was extracted from these clones, to analyze the nucleotide sequence of the DNA inserted into the clones.

The DNA had the nucleotide sequence represented by SEQ ID NO.6. In the DNA fragment was observed ORF encoding a peptide of 508 amino acids.

The peptide had an amino acid sequence in common with the rat-derived 25-hydroxyvitamin D₃-1 α -hydroxylase in terms of 413 amino acid residues, and contained amino acid sequences possibly corresponding to the hem binding region and adrenodoxin binding region, commonly observed in the P450 family protein.

Additionally, the DNA sequence included a sequence of 1724 residues, which is the same as the sequence derived from rats, and therefore, it was indicated that the DNA had high homology.

Example 8Expression of rat-derived vitamin D₃-1 α -hydroxylase gene and assay of the activity

5 According to the method of Example 6, gene expression plasmid carrying the rat-derived vitamin D₃-1 α -hydroxylase gene, namely pCMD3R, was introduced into COS-7 cell by electroporation.

The gene-introduced cells of 5×10^5 in number were cultivated in 10 ml of a DMEM culture medium containing 10 % FCS for 24 hours, and then, the culture medium was exchanged to a DMEM culture medium (8 ml) containing 1 % FCS, followed by addition of [26, 27-³H]-25-hydroxyvitamin D₃ (manufactured by Amersham, Co.) at 2000 Bq/3 μ l-methanol solution, and then, the resulting mixture was cultivated for 24 hours.

10 After cultivation, vitamin D₃ metabolites were extracted from the culture supernatant and the cells by the Bligh & Dyer's method [Can. J. Biochem., 37, 911 (1959)]. More specifically, the culture was transferred into a 50-ml centrifuge tube equipped with a screw cap, while 10 ml methanol was added into the petri dish, to scrape the cells with a scraper, and the cells were then transferred into the centrifuge tube. Methanol (10 ml) was again added into the petri dish, to suspend the cells remaining in the petri dish, and the resulting suspension was thoroughly transferred into the centrifuge tube.

Chloroform (10 ml) was added into the centrifuge tube for thorough mixing, followed by further addition of 10 ml of chloroform and subsequent complete re-mixing, and the resulting tube was left to stand to separate a chloroform layer from an aqueous layer.

20 The chloroform extract solution in the separated chloroform layer was placed in another centrifuge tube, followed by further addition of 10 ml of chloroform to the remaining aqueous layer, for mixing and extraction in the same manner, and the resulting chloroform extract solution was combined together with the previously recovered chloroform extract solution.

Distilled water was added into the chloroform extract solution to a final total volume of 60 ml, followed by addition of two drops of saturated sodium chloride solution and subsequent sufficient mixing.

The mixture solution was centrifuged, to separate the chloroform layer from the aqueous layer.

The resulting chloroform layer fraction was concentrated in nitrogen gas stream to recover the residue.

The residue was dissolved in 400 μ l of a mixture solution iso-propanol/methanol/n-hexane = 6 : 6 : 88.

30 With HPLC system 880 PU manufactured by JASCO, Co. with TSK silica gel 150 column (4.6 x 250 mm; manufactured by Toso, Co.) arranged thereon, the resulting solution was subject to analysis under conditions such that the mixture solution iso-propanol/methanol/n-hexane = 6 : 6 : 88 was used as the mobile phase at a flow rate of 1 ml/minute. On comparison with the elution time of a standard substance, vitamin D₃ metabolites were identified.

Similarly, vitamin D₃ metabolites were identified by using a vector pcDNA3 which does not carry the gene of the present invention.

35 The results are shown in Fig.1.

"A" represents the analytical results of metabolites in the cells introduced with pcMD3R; and "B" represents the analytical results of metabolites in the cells introduced with pcDNA3. Because 1 α , 25-hydroxyvitamin D₃ was detected only in the cells introduced with pcMD3R carrying the gene of the present invention, it was indicated that only the cells had 25-hydroxyvitamin D₃-1 α -hydroxylase activity, which further indicates that the gene of the present invention encodes 25-hydroxyvitamin D₃-1 α -hydroxylase.

40 In accordance with the present invention, the following can be provided; a polypeptide having 25-hydroxyvitamin D₃-1 α -hydroxylase activity, being useful for the prevention, diagnosis and therapeutic treatment of adult diseases such as osteoporosis induced by the decrease of active type vitamin D₃, DNA encoding the polypeptide, a recombinant DNA prepared by inserting the DNA in a vector, a transformant carrying the recombinant DNA, a method for preparing 25-hydroxyvitamin D₃-1 α -hydroxylase by using the transformant, a method for preparing 1 α , 25-dihydroxyvitamin D₃ by using the polypeptide having 25-hydroxyvitamin D₃-1 α -hydroxylase activity, and an antibody recognizing the polypeptide.

SEQUENCE LISTING

5 <110> KYOWA HAKKO KOGYO CO., LTD.
 6-1, Ohtemachi 1-chome, Chiyoda-ku, Tokyo 100, Japan
 10 <120> 25-HYDROXYVITAMIN D₃-1 α -HYDROXYLASE AND DNA
 ENCODING THE HYDROXYLASE
 <130> 1074
 15 <140>
 <141>
 20 <160> 9
 <170> PatentIn Ver. 2.0
 25 SEQ ID NO: 1
 <211> 501
 <212> PRT
 30 <213> Rat
 <400> 1
 Met Thr Gln Ala Val Lys Leu Ala Ser Arg Val Phe His Arg Val Gln
 35 1 5 10 15
 Leu Pro Ser Gln Leu Gly Ser Asp Ser Val Leu Arg Ser Leu Ser Asp
 40 20 25 30
 Ile Pro Gly Pro Ser Thr Pro Ser Phe Leu Ala Glu Leu Phe Cys Lys
 35 40 45
 45 Gly Gly Leu Ser Arg Leu His Glu Leu Gln Val His Gly Ala Ala Arg
 50 55 60
 50 Tyr Gly Pro Ile Trp Ser Gly Ser Phe Gly Thr Leu Arg Thr Val Tyr
 65 70 75 80
 55

Val Ala Asp Pro Ala Leu Val Glu Gln Leu Leu Arg Gln Glu Ser His
 85 90 95
 5
 Cys Pro Glu Arg Cys Ser Phe Ser Ser Trp Ser Glu His Arg Arg Arg
 100 105 110
 10
 His Gln Arg Ala Cys Gly Leu Leu Thr Ala Asp Gly Glu Glu Trp Gln
 115 120 125
 15
 Arg Leu Arg Ser Leu Leu Ala Pro Leu Leu Leu Arg Pro Gln Ala Ala
 130 135 140
 20
 Ala Gly Tyr Ala Gly Thr Leu Asp Ser Val Val Ser Asp Leu Val Arg
 145 150 155 160
 25
 Arg Leu Arg Arg Gln Arg Gly Arg Gly Ser Gly Leu Pro Asp Leu Val
 165 170 175
 30
 Leu Asp Val Ala Gly Glu Phe Tyr Lys Phe Gly Leu Glu Gly Ile Gly
 180 185 190
 35
 Ala Val Leu Leu Gly Ser Arg Leu Gly Cys Leu Glu Ala Glu Val Pro
 195 200 205
 40
 Pro Asp Thr Glu Thr Phe Ile Glu Ala Val Gly Ser Val Phe Val Ser
 210 215 220
 45
 Thr Leu Leu Thr Met Ala Met Pro Ser Trp Leu His Arg Leu Ile Pro
 225 230 235 240
 50
 Gly Pro Trp Ala Arg Leu Cys Arg Asp Trp Asp Gln Met Phe Ala Phe
 245 250 255
 55
 Ala Gln Lys His Val Glu Gln Arg Glu Gly Glu Ala Ala Val Arg Asn
 260 265 270

EP 0 890 643 A2

5 Gln Gly Lys Pro Glu Glu Asp Leu Pro Thr Gly His His Leu Thr His
 275 280 285
 10 Phe Leu Phe Arg Glu Lys Val Ser Val Gln Ser Ile Val Gly Asn Val
 290 295 300
 15 Thr Glu Leu Leu Leu Ala Gly Val Asp Thr Val Ser Asn Thr Leu Ser
 305 310 315 320
 20 Trp Ala Leu Tyr Glu Leu Ser Arg His Pro Glu Val Gln Ser Ala Leu
 325 330 335
 25 His Ser Glu Ile Thr Gly Ala Val Asn Pro Gly Ser Tyr Ala His Leu
 340 345 350
 30 Gln Ala Thr Ala Leu Ser Gln Leu Pro Leu Leu Lys Ala Val Ile Lys
 355 360 365
 35 Glu Val Leu Arg Leu Tyr Pro Val Val Pro Gly Asn Ser Arg Val Pro
 370 375 380
 40 Asp Arg Asp Ile Cys Val Gly Asn Tyr Val Ile Pro Gln Asp Thr Leu
 385 390 395 400
 45 Val Ser Leu Cys His Tyr Ala Thr Ser Arg Asp Pro Ala Gln Phe Arg
 405 410 415
 50 Glu Pro Asn Ser Phe Asn Pro Ala Arg Trp Leu Gly Glu Gly Pro Ala
 420 425 430
 55 Pro His Pro Phe Ala Ser Leu Pro Phe Gly Phe Gly Lys Arg Ser Cys
 435 440 445
 60 Ile Gly Arg Arg Leu Ala Glu Leu Glu Leu Gln Met Ala Leu Ala Gln
 450 455 460

EP 0 890 643 A2

5 Ile Leu Thr His Phe Glu Val Leu Pro Glu Pro Gly Ala Leu Pro Val
 465 470 475 480
 Lys Pro Met Thr Arg Thr Val Leu Val Pro Glu Arg Ser Ile His Leu
 485 490 495
 10 Gln Phe Val Asp Arg
 500
 15
 SEQ ID NO: 2
 20 <211> 508
 <212> PRT
 <213> human
 25 <400> 2
 Met Thr Gln Thr Leu Lys Tyr Ala Ser Arg Val Phe His Arg Val Arg
 30 1 5 10 15
 Trp Ala Pro Glu Leu Gly Ala Ser Leu Gly Tyr Arg Glu Tyr His Ser
 35 20 25 30
 Ala Arg Arg Ser Leu Ala Asp Ile Pro Gly Pro Ser Thr Pro Ser Phe
 40 35 40 45
 Leu Ala Glu Leu Phe Cys Lys Gly Gly Leu Ser Arg Leu His Glu Leu
 45 50 55 60
 Gln Val Gln Gly Ala Ala His Phe Gly Pro Val Trp Leu Ala Ser Phe
 50 65 70 75 80
 Gly Thr Val Arg Thr Val Tyr Val Ala Ala Pro Ala Leu Val Glu Glu
 85 90 95

THIS PAGE BLANK (USPTO)

5 Leu Leu Arg Gln Glu Gly Pro Arg Pro Glu Arg Cys Ser Phe Ser Pro
 100 105 110

10 Trp Thr Glu His Arg Arg Cys Arg Gln Arg Ala Cys Gly Leu Leu Thr
 115 120 125

15 Ala Glu Gly Glu Glu Trp Gln Arg Leu Arg Ser Leu Leu Ala Pro Leu
 130 135 140

20 Leu Leu Arg Pro Gln Ala Ala Ala Arg Tyr Ala Gly Thr Leu Asn Asn
 145 150 155 160

25 Val Val Cys Asp Leu Val Arg Arg Leu Arg Arg Gln Arg Gly Arg Gly
 165 170 175

30 Thr Gly Pro Pro Ala Leu Val Arg Asp Val Ala Gly Glu Phe Tyr Lys
 180 185 190

35 Phe Gly Leu Glu Gly Ile Ala Ala Val Leu Leu Gly Ser Arg Leu Gly
 195 200 205

40 Cys Leu Glu Ala Gln Val Pro Pro Asp Thr Glu Thr Phe Ile Arg Ala
 210 215 220

45 Val Gly Ser Val Phe Val Ser Thr Leu Leu Thr Met Ala Met Pro His
 225 230 235 240

50 Trp Leu Arg His Leu Val Pro Gly Pro Trp Gly Arg Leu Cys Arg Asp
 245 250 255

55 Trp Asp Gln Met Phe Ala Phe Ala Gln Arg His Val Glu Arg Arg Glu
 260 265 270

Ala Glu Ala Ala Met Arg Asn Gly Gly Gln Pro Glu Lys Asp Leu Glu
 275 280 285

Ser Gly Ala His Leu Thr His Phe Leu Phe Arg Glu Glu Leu Pro Ala
 290 295 300
 5
 Gln Ser Ile Leu Gly Asn Val Thr Glu Leu Leu Leu Ala Gly Val Asp
 305 310 315 320
 10
 Thr Val Ser Asn Thr Leu Ser Trp Ala Leu Tyr Glu Leu Ser Arg His
 325 330 335
 15
 Pro Glu Val Gln Thr Ala Leu His Ser Glu Ile Thr Ala Ala Leu Ser
 340 345 350
 20
 Pro Gly Ser Ser Ala Tyr Pro Ser Ala Thr Val Leu Ser Gln Leu Pro
 355 360 365
 25
 Leu Leu Lys Ala Val Val Lys Glu Val Leu Arg Leu Tyr Pro Val Val
 370 375 380
 30
 Pro Gly Asn Ser Arg Val Pro Asp Lys Asp Ile His Val Gly Asp Tyr
 385 390 395 400
 35
 Ile Ile Pro Lys Asn Thr Leu Val Thr Leu Cys His Tyr Ala Thr Ser
 405 410 415
 40
 Arg Asp Pro Ala Gln Phe Pro Glu Pro Asn Ser Phe Arg Pro Ala Arg
 420 425 430
 45
 Trp Leu Gly Glu Gly Pro Thr Pro His Pro Phe Ala Ser Leu Pro Phe
 435 440 445
 50
 Gly Phe Gly Lys Arg Ser Cys Met Gly Arg Arg Leu Ala Glu Leu Glu
 450 455 460
 55
 Leu Gln Met Ala Leu Ala Gln Ile Leu Thr His Phe Glu Val Gln Pro
 465 470 475 480

EP 0 890 643 A2

Glu Pro Gly Ala Ala Pro Val Arg Pro Lys Thr Arg Thr Val Leu Val
485 490 495

Pro Glu Arg Ser Ile Asn Leu Gln Phe Leu Asp Arg
500 505

SEQ ID NO: 3

<211> 1503

<212> DNA

<213> Rat

<220>

<221> CDS

<222> (1) .. (1503)

<400> 3

atg acc cag gca gtc aag ctc gcc tcc aga gtc ttc cat cga gtc caa 48

Met Thr Gln Ala Val Lys Leu Ala Ser Arg Val Phe His Arg Val Gln

1 5 10 15

ctg cct tct cag ctg gcc agt gac tcg gtt ctc cgg agt tta tct gat 96

Leu Pro Ser Gln Leu Gly Ser Asp Ser Val Leu Arg Ser Leu Ser Asp

20 25 30

atc cct ggg ccc tct aca cct agc ttc ctg gct gaa ctc ttc tgc aaa 144

Ile Pro Gly Pro Ser Thr Pro Ser Phe Leu Ala Glu Leu Phe Cys Lys

35 40 45

ggg ggg ctg tcc agg cta cat gaa ctg cag gtg cat ggc gct gcg cgg 192

Gly Gly Leu Ser Arg Leu His Glu Leu Gln Val His Gly Ala Ala Arg

50 55 60

tac ggg cca ata tgg tcc ggc agc ttc ggg aca ctt cgc aca gtt tat 240

Tyr Gly Pro Ile Trp Ser Gly Ser Phe Gly Thr Leu Arg Thr Val Tyr

65 70 75 80

EP 0 890 643 A2

gtg gcc gac cct gca ctt gta gag cag ctc ctg cga caa gaa agt cat 288
Val Ala Asp Pro Ala Leu Val Glu Gln Leu Leu Arg Gln Glu Ser His
5 85 90 95

tgt cca gag cgc tgt agt ttc tca tct tgg tca gag cac cgt cgc cgc 336
10 Cys Pro Glu Arg Cys Ser Phe Ser Ser Trp Ser Glu His Arg Arg Arg
100 105 110

cac cag cgg gct tgc ggg ttg cta acg gcg gat ggt gaa gaa tgg cag 384
15 His Gln Arg Ala Cys Gly Leu Leu Thr Ala Asp Gly Glu Glu Trp Gln
115 120 125

agg ctc cga agt ctc ctg gcc ccg cta ctc ctc cga cct caa gca gcc 432
20 Arg Leu Arg Ser Leu Leu Ala Pro Leu Leu Leu Arg Pro Gln Ala Ala
130 135 140

gcc ggc tat gct gga act ctg gac agc gtg gtc agt gac ctc gtg cga 480
25 Ala Gly Tyr Ala Gly Thr Leu Asp Ser Val Val Ser Asp Leu Val Arg
145 150 155 160

cga cta agg cgc cag cgg gga cgt ggc tct ggg cta ccg gac cta gtt 528
30 Arg Leu Arg Arg Gln Arg Gly Arg Gly Ser Gly Leu Pro Asp Leu Val
35 165 170 175

ctg gac gtg gcg gga gag ttt tac aaa ttt ggc cta gaa ggc ata ggc 576
40 Leu Asp Val Ala Gly Glu Phe Tyr Lys Phe Gly Leu Glu Gly Ile Gly
180 185 190

gcg gtg ctg ctg gga tcg cgc ctg ggc tgc ctg gag gct gaa gtt cct 624
45 Ala Val Leu Leu Gly Ser Arg Leu Gly Cys Leu Glu Ala Glu Val Pro
195 200 205

ccc gac aca gaa acc ttc att gag gcc gtg ggc tcg gtg ttt gtg tct 672
50 Pro Asp Thr Glu Thr Phe Ile Glu Ala Val Gly Ser Val Phe Val Ser
210 215 220

55

EP 0 890 643 A2

5 aca ctc ttg acc atg gca atg ccc agt tgg ctg cac cgc ctt ata ccc 720
 Thr Leu Leu Thr Met Ala Met Pro Ser Trp Leu His Arg Leu Ile Pro
 225 230 235 240

10 gga ccc tgg gcc cgc ctc tgc aga gac tgg gat cag atg ttt gcc ttt 768
 Gly Pro Trp Ala Arg Leu Cys Arg Asp Trp Asp Gln Met Phe Ala Phe
 245 250 255

15 gcc cag aag cac gtg gag cag cgc gaa ggc gaa gct gcc gtg agg aac 816
 Ala Gln Lys His Val Glu Gln Arg Glu Gly Glu Ala Ala Val Arg Asn
 260 265 270

20 cag gga aag cct gag gag gat ttg cca acg ggg cat cac tta acc cac 864
 Gln Gly Lys Pro Glu Glu Asp Leu Pro Thr Gly His His Leu Thr His
 275 280 285

25 ttc ctt ttt cgg gaa aag gtg tct gtc cag tcc ata gtg gga aat gtg 912
 Phe Leu Phe Arg Glu Lys Val Ser Val Gln Ser Ile Val Gly Asn Val
 290 295 300

30 aca gag cta cta ctg gct gga gtg gac acg gta tcc aat acg ctc tcc 960
 Thr Glu Leu Leu Leu Ala Gly Val Asp Thr Val Ser Asn Thr Leu Ser
 305 310 315 320

35 tgg gca ctc tat gag ctc tcc cgg cac ccg gaa gtc cag tct gca ctc 1008
 Trp Ala Leu Tyr Glu Leu Ser Arg His Pro Glu Val Gln Ser Ala Leu
 325 330 335

40 cac tct gag atc aca ggc gct gtg aac cct ggc tcc tat gcc cac ctc 1056
 His Ser Glu Ile Thr Gly Ala Val Asn Pro Gly Ser Tyr Ala His Leu
 340 345 350

45 caa gcc act gct ctg tcc cag cta ccc ctg cta aag gct gtg atc aaa 1104
 Gln Ala Thr Ala Leu Ser Gln Leu Pro Leu Leu Lys Ala Val Ile Lys
 355 360 365

50

55

5 gaa gtg ttg aga ttg tac cct gtg gta cct ggg aac tcc cgt gtc cca 1152
 Glu Val Leu Arg Leu Tyr Pro Val Val Pro Gly Asn Ser Arg Val Pro
 370 375 380

10 gac aga gac atc tgt gta gga aac tat gtt att ccc caa gat aca ctg 1200
 Asp Arg Asp Ile Cys Val Gly Asn Tyr Val Ile Pro Gln Asp Thr Leu
 385 390 395 400

15 gtt tcc ctc tgt cac tat gcc act tca agg gac ccc gcc cag ttt cgg 1248
 Val Ser Leu Cys His Tyr Ala Thr Ser Arg Asp Pro Ala Gln Phe Arg
 405 410 415

20 gaa ccc aac tct ttt aat cca gct cga tgg ctt gga gag ggt cca gcc 1296
 Glu Pro Asn Ser Phe Asn Pro Ala Arg Trp Leu Gly Glu Gly Pro Ala
 420 425 430

25 ccc cac cca ttt gca tct ctt cct ttt ggc ttt ggc aaa cga agt tgc 1344
 Pro His Pro Phe Ala Ser Leu Pro Phe Gly Phe Gly Lys Arg Ser Cys
 435 440 445

30 ata ggg aga cgc ttg gca gag ctc gag cta caa atg gcg ttg gcc cag 1392
 Ile Gly Arg Arg Leu Ala Glu Leu Glu Leu Gln Met Ala Leu Ala Gln
 35 450 455 460

40 atc ttg acc cat ttt gag gtg ctg cct gag cca ggt gct ctt cca gtc 1440
 Ile Leu Thr His Phe Glu Val Leu Pro Glu Pro Gly Ala Leu Pro Val
 465 470 475 480

45 aaa ccc atg acc cgg act gtc ctg gta cct gag agg agc atc cat ctc 1488
 Lys Pro Met Thr Arg Thr Val Leu Val Pro Glu Arg Ser Ile His Leu
 485 490 495

50 cag ttt gta gac aga 1503
 Gln Phe Val Asp Arg
 500

55

SEQ ID NO: 4

<211> 1524

<212> DNA

<213> human

<220>

<221> CDS

<222> (1) .. (1524)

<400> 4

```

5
10
15
20 atg acc cag acc ctc aag tac gcc tcc aga gtg ttc cat cgc gtc cgc 48
    Met Thr Gln Thr Leu Lys Tyr Ala Ser Arg Val Phe His Arg Val Arg
      1           5           10           15

25 tgg gcg ccc gag ttg ggc gcc tcc cta ggc tac cga gag tac cac tca 96
    Trp Ala Pro Glu Leu Gly Ala Ser Leu Gly Tyr Arg Glu Tyr His Ser
          20           25           30

30 gca cgc cgg agc ttg gca gac atc cca ggc ccc tct acg ccc agc ttt 144
    Ala Arg Arg Ser Leu Ala Asp Ile Pro Gly Pro Ser Thr Pro Ser Phe
          35           40           45

35 ctg gcc gaa ctt ttc tgc aag ggg ggg ctg tcg agg cta cac gag ctg 192
    Leu Ala Glu Leu Phe Cys Lys Gly Gly Leu Ser Arg Leu His Glu Leu
      40           50           55           60

45 cag gtg cag ggc gcc gcg cac ttc ggg ccg gtg tgg cta gcc agc ttt 240
    Gln Val Gln Gly Ala Ala His Phe Gly Pro Val Trp Leu Ala Ser Phe
      65           70           75           80

50 ggg aca gtg cgc acc gtg tac gtg gct gcc cct gca ctc gtc gag gag 288
    Gly Thr Val Arg Thr Val Tyr Val Ala Ala Pro Ala Leu Val Glu Glu
          85           90           95

55

```

5	ctg ctg cga cag gag gga ccc cgg ccc gag cgc tgc agc ttc tcg ccc Leu Leu Arg Gln Glu Gly Pro Arg Pro Glu Arg Cys Ser Phe Ser Pro	336
	100 105 110	
10	tgg acg gag cac cgc cgc tgc cgc cag cgg gct tgc gga ctg ctc act Trp Thr Glu His Arg Arg Cys Arg Gln Arg Ala Cys Gly Leu Leu Thr	384
	115 120 125	
15	gcg gaa ggc gaa gaa tgg caa agg ctc cgc agt ctc ctg gcc ccg ctc Ala Glu Gly Glu Glu Trp Gln Arg Leu Arg Ser Leu Leu Ala Pro Leu	432
	130 135 140	
20	ctc ctc cgg cct caa gcg gcc gcc cgc tac gcc gga acc ctg aac aac Leu Leu Arg Pro Gln Ala Ala Ala Arg Tyr Ala Gly Thr Leu Asn Asn	480
	145 150 155 160	
25	gta gtc tgc gac ctt gtg cgg cgt ctg agg cgc cag cgg gga cgt ggc Val Val Cys Asp Leu Val Arg Arg Leu Arg Arg Gln Arg Gly Arg Gly	528
	165 170 175	
30	acg ggg ccg ccc gcc ctg gtt cgg gac gtg gcg ggg gaa ttt tac aag Thr Gly Pro Pro Ala Leu Val Arg Asp Val Ala Gly Glu Phe Tyr Lys	576
35	180 185 190	
40	ttc gga ctg gaa ggc atc gcc gcg gtt ctg ctc ggc tcg cgc ttg ggc Phe Gly Leu Glu Gly Ile Ala Ala Val Leu Leu Gly Ser Arg Leu Gly	624
	195 200 205	
45	tgc ctg gag gct caa gtg cca ccc gac acg gag acc ttc atc cgc gct Cys Leu Glu Ala Gln Val Pro Pro Asp Thr Glu Thr Phe Ile Arg Ala	672
	210 215 220	
50	gtg ggc tcg gtg ttt gtg tcc acg ctg ttg acc atg gcg atg ccc cac Val Gly Ser Val Phe Val Ser Thr Leu Leu Thr Met Ala Met Pro His	720
	225 230 235 240	

55

5 tgg ctg cgc cac ctt gtg cct ggg ccc tgg ggc cgc ctc tgc cga gac 768
 Trp Leu Arg His Leu Val Pro Gly Pro Trp Gly Arg Leu Cys Arg Asp
 245 250 255

10 tgg gac cag atg ttt gca ttt gct cag agg cac gtg gag cgg cga gag 816
 Trp Asp Gln Met Phe Ala Phe Ala Gln Arg His Val Glu Arg Arg Glu
 260 265 270

15 gca gag gca gcc atg agg aac gga gga cag ccc gag aag gac ctg gag 864
 Ala Glu Ala Ala Met Arg Asn Gly Gly Gln Pro Glu Lys Asp Leu Glu
 275 280 285

20 tct ggg gcg cac ctg acc cac ttc ctg ttc cgg gaa gag ttg cct gcc 912
 Ser Gly Ala His Leu Thr His Phe Leu Phe Arg Glu Glu Leu Pro Ala
 290 295 300

25 cag tcc atc ctg gga aat gtg aca gag ttg cta ttg gcg gga gtg gac 960
 Gln Ser Ile Leu Gly Asn Val Thr Glu Leu Leu Leu Ala Gly Val Asp
 305 310 315 320

30 acg gtg tcc aac acg ctc tct tgg gct ctg tat gag ctc tcc cgg cac 1008
 Thr Val Ser Asn Thr Leu Ser Trp Ala Leu Tyr Glu Leu Ser Arg His
 35 325 330 335

40 ccc gaa gtc cag aca gca ctc cac tca gag atc aca gct gcc ctg agc 1056
 Pro Glu Val Gln Thr Ala Leu His Ser Glu Ile Thr Ala Ala Leu Ser
 340 345 350

45 cct ggc tcc agt gcc tac ccc tca gcc act gtt ctg tcc cag ctg ccc 1104
 Pro Gly Ser Ser Ala Tyr Pro Ser Ala Thr Val Leu Ser Gln Leu Pro
 355 360 365

50 ctg ctg aag gcg gtg gtc aag gaa gtg cta aga ctg tac cct gtg gta 1152
 Leu Leu Lys Ala Val Val Lys Glu Val Leu Arg Leu Tyr Pro Val Val
 370 375 380

55

5 cct gga aat tct cgt gtc cca gac aaa gac att cat gtg ggt gac tat 1200
 Pro Gly Asn Ser Arg Val Pro Asp Lys Asp Ile His Val Gly Asp Tyr
 385 390 395 400

10 att atc ccc aaa aat acg ctg gtc act ctg tgt cac tat gcc act tca 1248
 Ile Ile Pro Lys Asn Thr Leu Val Thr Leu Cys His Tyr Ala Thr Ser
 405 410 415

15 agg gac cct gcc cag ttc cca gag cca aat tct ttt cgt cca gct cgc 1296
 Arg Asp Pro Ala Gln Phe Pro Glu Pro Asn Ser Phe Arg Pro Ala Arg
 420 425 430

20 tgg ctg ggg gag ggt ccc acc ccc cac cca ttt gca tct ctt ccc ttt 1344
 Trp Leu Gly Glu Gly Pro Thr Pro His Pro Phe Ala Ser Leu Pro Phe
 435 440 445

25 ggc ttt ggc aag cgc agc tgt atg ggg aga cgc ctg gca gag ctt gaa 1392
 Gly Phe Gly Lys Arg Ser Cys Met Gly Arg Arg Leu Ala Glu Leu Glu
 450 455 460

30 ttg caa atg gct ttg gcc cag atc cta aca cat ttt gag gtg cag cct 1440
 Leu Gln Met Ala Leu Ala Gln Ile Leu Thr His Phe Glu Val Gln Pro
 35 465 470 475 480

40 gag cca ggt gcg gcc cca gtt aga ccc aag acc cgg act gtc ctg gta 1488
 Glu Pro Gly Ala Ala Pro Val Arg Pro Lys Thr Arg Thr Val Leu Val
 485 490 495

45 cct gaa agg agc atc aac cta cag ttt ttg gac aga 1524
 Pro Glu Arg Ser Ile Asn Leu Gln Phe Leu Asp Arg
 500 505

50 SEQ ID NO: 5
 <211> 2469

55

<212> DNA

<213> Rat

5

<220>

<221> CDS

10

<222> (24) .. (1526)

<400> 5

gagcagactc ctcaaacaca aac atg acc cag gca gtc aag ctc gcc tcc aga 53

15

Met Thr Gln Ala Val Lys Leu Ala Ser Arg

1

5

10

20

gtc ttc cat cga gtc caa ctg cct tct cag ctg ggc agt gac tcg gtt 101

Val Phe His Arg Val Gln Leu Pro Ser Gln Leu Gly Ser Asp Ser Val

15

20

25

25

ctc cgg agt tta tct gat atc cct ggg ccc tct aca cct agc ttc ctg 149

Leu Arg Ser Leu Ser Asp Ile Pro Gly Pro Ser Thr Pro Ser Phe Leu

30

35

40

30

gct gaa ctc ttc tgc aaa ggg ggg ctg tcc agg cta cat gaa ctg cag 197

Ala Glu Leu Phe Cys Lys Gly Gly Leu Ser Arg Leu His Glu Leu Gln

35

45

50

55

gtg cat ggc gct gcg cgg tac ggg cca ata tgg tcc ggc agc ttc ggg 245

Val His Gly Ala Ala Arg Tyr Gly Pro Ile Trp Ser Gly Ser Phe Gly

40

60

65

70

aca ctt cgc aca gtt tat gtg gcc gac cct gca ctt gta gag cag ctc 293

45

Thr Leu Arg Thr Val Tyr Val Ala Asp Pro Ala Leu Val Glu Gln Leu

75

80

85

90

50

ctg cga caa gaa agt cat tgt cca gag cgc tgt agt ttc tca tct tgg 341

Leu Arg Gln Glu Ser His Cys Pro Glu Arg Cys Ser Phe Ser Ser Trp

95

100

105

55

	tca gag cac cgt cgc cgc cac cag cgg gct tgc ggg ttg cta acg gcg	389
	Ser Glu His Arg Arg Arg His Gln Arg Ala Cys Gly Leu Leu Thr Ala	
5	110 115 120	
	gat ggt gaa gaa tgg cag agg ctc cga agt ctc ctg gcc ccg cta ctc	437
10	Asp Gly Glu Glu Trp Gln Arg Leu Arg Ser Leu Leu Ala Pro Leu Leu	
	125 130 135	
	ctc cga cct caa gca gcc gcc ggc tat gct gga act ctg gac agc gtg	485
15	Leu Arg Pro Gln Ala Ala Ala Gly Tyr Ala Gly Thr Leu Asp Ser Val	
	140 145 150	
	gtc agt gac ctc gtg cga cga cta agg cgc cag cgg gga cgt ggc tct	533
20	Val Ser Asp Leu Val Arg Arg Leu Arg Arg Gln Arg Gly Arg Gly Ser	
	155 160 165 170	
	ggg cta ccg gac cta gtt ctg gac gtg gcg gga gag ttt tac aaa ttt	581
25	Gly Leu Pro Asp Leu Val Leu Asp Val Ala Gly Glu Phe Tyr Lys Phe	
	175 180 185	
30	ggc cta gaa ggc ata ggc gcg gtg ctg ctg gga tcg cgc ctg ggc tgc	629
	Gly Leu Glu Gly Ile Gly Ala Val Leu Leu Gly Ser Arg Leu Gly Cys	
35	190 195 200	
	ctg gag gct gaa gtt cct ccc gac aca gaa acc ttc att gag gcc gtg	677
40	Leu Glu Ala Glu Val Pro Pro Asp Thr Glu Thr Phe Ile Glu Ala Val	
	205 210 215	
	ggc tcg gtg ttt gtg tct aca ctc ttg acc atg gca atg ccc agt tgg	725
45	Gly Ser Val Phe Val Ser Thr Leu Leu Thr Met Ala Met Pro Ser Trp	
	220 225 230	
	ctg cac cgc ctt ata ccc gga ccc tgg gcc cgc ctc tgc aga gac tgg	773
50	Leu His Arg Leu Ile Pro Gly Pro Trp Ala Arg Leu Cys Arg Asp Trp	
	235 240 245 250	

55

5 gat cag arg ttt gcc ttt gcc cag aag cac gtg gag cag cgc gaa ggc 821
 Asp Gln Met Phe Ala Phe Ala Gln Lys His Val Glu Gln Arg Glu Gly
 255 260 265

10 gaa gct gcc gtg agg aac cag gga aag cct gag gag gat ttg cca acg 869
 Glu Ala Ala Val Arg Asn Gln Gly Lys Pro Glu Glu Asp Leu Pro Thr
 270 275 280

15 ggg cat cac tta acc cac ttc ctt ttt cgg gaa aag gtg tct gtc cag 917
 Gly His His Leu Thr His Phe Leu Phe Arg Glu Lys Val Ser Val Gln
 285 290 295

20 tcc ata gtg gga aat gtg aca gag cta cta ctg gct gga gtg gac acg 965
 Ser Ile Val Gly Asn Val Thr Glu Leu Leu Leu Ala Gly Val Asp Thr
 300 305 310

25 gta tcc aat acg ctc tcc tgg gca ctc tat gag ctc tcc cgg cac ccg 1013
 Val Ser Asn Thr Leu Ser Trp Ala Leu Tyr Glu Leu Ser Arg His Pro
 315 320 325 330

30 gaa gtc cag tct gca ctc cac tct gag atc aca ggc gct gtg aac cct 1061
 Glu Val Gln Ser Ala Leu His Ser Glu Ile Thr Gly Ala Val Asn Pro
 335 340 345

35 ggc tcc tat gcc cac ctc caa gcc act gct ctg tcc cag cta ccc ctg 1109
 Gly Ser Tyr Ala His Leu Gln Ala Thr Ala Leu Ser Gln Leu Pro Leu
 350 355 360

40 cta aag gct gtg atc aaa gaa gtg ttg aga ttg tac cct gtg gta cct 1157
 Leu Lys Ala Val Ile Lys Glu Val Leu Arg Leu Tyr Pro Val Val Pro
 365 370 375

45 ggg aac tcc cgt gtc cca gac aga gac atc tgt gta gga aac tat gtt 1205
 Gly Asn Ser Arg Val Pro Asp Arg Asp Ile Cys Val Gly Asn Tyr Val
 380 385 390

50

55

att ccc caa gat aca ctg gtt tcc ctc tgt cac tat gcc act tca agg 1253
 Ile Pro Gln Asp Thr Leu Val Ser Leu Cys His Tyr Ala Thr Ser Arg
 5 395 400 405 410

gac ccc gcc cag ttt cgg gaa ccc aac tct ttt aat cca gct cga tgg 1301
 Asp Pro Ala Gln Phe Arg Glu Pro Asn Ser Phe Asn Pro Ala Arg Trp
 10 415 420 425

ctt gga gag ggt cca gcc ccc cac cca ttt gca tct ctt cct ttt ggc 1349
 Leu Gly Glu Gly Pro Ala Pro His Pro Phe Ala Ser Leu Pro Phe Gly
 15 430 435 440

ttt ggc aaa cga agt tgc ata ggg aga cgc ttg gca gag ctc gag cta 1397
 Phe Gly Lys Arg Ser Cys Ile Gly Arg Arg Leu Ala Glu Leu Glu Leu
 20 445 450 455

caa atg gcg ttg gcc cag atc ttg acc cat ttt gag gtg ctg cct gag 1445
 Gln Met Ala Leu Ala Gln Ile Leu Thr His Phe Glu Val Leu Pro Glu
 25 460 465 470

cca ggt gct ctt cca gtc aaa ccc atg acc cgg act gtc ctg gta cct 1493
 Pro Gly Ala Leu Pro Val Lys Pro Met Thr Arg Thr Val Leu Val Pro
 30 475 480 485 490

gag agg agc atc cat ctc cag ttt gta gac aga tagtcctgtg gaaggcagct 1546
 Glu Arg Ser Ile His Leu Gln Phe Val Asp Arg
 40 495 500

gtcacatct ctctccagac tggatttttc ttactatgca caagaggcac actctccctc 1606

gaggcctgtc tgtctgagca aacttcagga agcaggcccg ggcctatctg tgcttgacct 1666

gactcagcag gtaccacaga accaggatcc tttctcctgc tcagtacctc tcctgatcat 1726

tcctcaagat ccaaagcctt cagattttta cacatcctta aaggccaac tcgggggtta 1786

55

actaacagcc ccaggcagcc tgggcagga tccccactg atccttccat gcttacagt 1846
 5 ttcactgaca gctgtctaaag catccattgc agcacaact aagtgactgt gcacctggc 1906
 tgcacctggc ctgcacctgg ttgcgtctct gcctgacct gtgagctctt tgagaagagt 1966
 10 gatgactact gggcttttag ctttttctt ttttgggaca cagtcttgct attgtactcc 2026
 atgtgtctct tgaaccaca agccctcacc tcaccttccc aagtgttggg ttacggacat 2086
 15 tagctatggc ttccagcttt attagctttt ctatctctg ccatggtcta tccccggcta 2146
 tttgatacta tatattctca gattgaatct ggacctgtg gtagaaggga tgacctca 2206
 ccaggctcta cccaccactt tatcttaac ttttctctag gaaagtgaat ctctcctgc 2266
 25 cttacagcat tttaaagctc cccttggctg ttctgctctt tagccactct aaagtggatc 2326
 cactctactt ctcaccaccc atctttctgc acccagcct gtctttttat atttaaaaaa 2386
 30 ttgtatttat tatgttttca aataaaatgt ttactcctg aaaaaaaaaa aaaaaaaaaa 2446
 35 aaaaaaaaaa aaaaaaaaaa aaa 2469

40 SEQ ID NO: 6
 <211> 2469
 <212> DNA
 45 <213> human
 <220>
 50 <221> CDS
 <222> (122) .. (1545)

55

<400> 6
 aggagggatt ggctgaggag cttggagagg gggcgtcatc acccaccaca aaggttaa 60
 5
 aggggttgag atatgatgct caggagaagc gctttcttc gcgagacccc tgaaccagac 120
 10
 c atg acc cag acc ctc aag tac gcc tcc aga gtg ttc cat cgc gtc cgc 169
 Met Thr Gln Thr Leu Lys Tyr Ala Ser Arg Val Phe His Arg Val Arg
 1 5 10 15
 15
 tgg gcg ccc gag ttg ggc gcc tcc cta ggc tac cga gag tac cac tca 217
 Trp Ala Pro Glu Leu Gly Ala Ser Leu Gly Tyr Arg Glu Tyr His Ser
 20 25 30
 20
 gca cgc cgg agc ttg gca gac atc cca ggc ccc tct acg ccc agc ttt 265
 Ala Arg Arg Ser Leu Ala Asp Ile Pro Gly Pro Ser Thr Pro Ser Phe
 35 40 45
 25
 ctg gcc gaa ctt ttc tgc aag ggg ggg ctg tgc agg cta cac gag ctg 313
 Leu Ala Glu Leu Phe Cys Lys Gly Gly Leu Ser Arg Leu His Glu Leu
 50 55 60
 30
 cag gtg cag ggc gcc gcg cac ttc ggg ccg gtg tgg cta gcc agc ttt 361
 Gln Val Gln Gly Ala Ala His Phe Gly Pro Val Trp Leu Ala Ser Phe
 35 65 70 75 80
 ggg aca gtg cgc acc gtg tac gtg gct gcc cct gca ctc gtc gag gag 409
 Gly Thr Val Arg Thr Val Tyr Val Ala Ala Pro Ala Leu Val Glu Glu
 40 85 90 95
 ctg ctg cga cag gag gga ccc cgg ccc gag cgc tgc agc ttc tgc ccc 457
 45
 Leu Leu Arg Gln Glu Gly Pro Arg Pro Glu Arg Cys Ser Phe Ser Pro
 100 105 110
 tgg acg gag cac cgc cgc tgc cgc cag cgg gct tgc gga ctg ctc act 505
 50
 Trp Thr Glu His Arg Arg Cys Arg Gln Arg Ala Cys Gly Leu Leu Thr
 115 120 125
 55

EP 0 890 643 A2

5	gcg gaa ggc gaa gaa tgg caa agg ctc cgc agt ctc ctg gcc ccg ctc Ala Glu Gly Glu Glu Trp Gln Arg Leu Arg Ser Leu Leu Ala Pro Leu	553
	130 135 140	
10	ctc ctc cgg cct caa gcg gcc gcc cgc tac gcc gga acc ctg aac aac Leu Leu Arg Pro Gln Ala Ala Ala Arg Tyr Ala Gly Thr Leu Asn Asn	601
	145 150 155 160	
15	gta gtc tgc gac ctt gtg cgg cgt ctg agg cgc cag cgg gga cgt ggc Val Val Cys Asp Leu Val Arg Arg Leu Arg Arg Gln Arg Gly Arg Gly	649
	165 170 175	
20	acg ggg ccg ccc gcc ctg gtt cgg gac gtg gcg ggg gaa ttt tac aag Thr Gly Pro Pro Ala Leu Val Arg Asp Val Ala Gly Glu Phe Tyr Lys	697
	180 185 190	
25	ttc gga ctg gaa ggc atc gcc gcg gtt ctg ctc ggc tcg cgc ttg ggc Phe Gly Leu Glu Gly Ile Ala Ala Val Leu Leu Gly Ser Arg Leu Gly	745
	195 200 205	
30	gtc ctg gag gct caa gtg cca ccc gac acg gag acc ttc atc cgc gct Cys Leu Glu Ala Gln Val Pro Pro Asp Thr Glu Thr Phe Ile Arg Ala	793
35	210 215 220	
40	gtg ggc tcg gtg ttt gtg tcc acg ctg ttg acc atg gcg atg ccc cac Val Gly Ser Val Phe Val Ser Thr Leu Leu Thr Met Ala Met Pro His	841
	225 230 235 240	
45	tgg ctg cgc cac ctt gtg cct ggg ccc tgg ggc cgc ctc tgc cga gac Trp Leu Arg His Leu Val Pro Gly Pro Trp Gly Arg Leu Cys Arg Asp	889
	245 250 255	
50	tgg gac cag atg ttt gca ttt gct cag agg cac gtg gag cgg cga gag Trp Asp Gln Met Phe Ala Phe Ala Gln Arg His Val Glu Arg Arg Glu	937
	260 265 270	

55

5 gca gag gca gcc atg agg aac gga gga cag ccc gag aag gac ctg gag 985
 Ala Glu Ala Ala Met Arg Asn Gly Gly Gln Pro Glu Lys Asp Leu Glu
 275 280 285

10 tct ggg gcg cac ctg acc cac ttc ctg ttc cgg gaa gag ttg cct gcc 1033
 Ser Gly Ala His Leu Thr His Phe Leu Phe Arg Glu Glu Leu Pro Ala
 290 295 300

15 cag tcc atc ctg gga aat gtg aca gag ttg cta ttg gcg gga gtg gac 1081
 Gln Ser Ile Leu Gly Asn Val Thr Glu Leu Leu Leu Ala Gly Val Asp
 305 310 315 320

20 acg gtg tcc aac acg ctc tct tgg gct ctg tat gag ctc tcc cgg cac 1129
 Thr Val Ser Asn Thr Leu Ser Trp Ala Leu Tyr Glu Leu Ser Arg His
 325 330 335

25 ccc gaa gtc cag aca gca ctc cac tca gag atc aca gct gcc ctg agc 1177
 Pro Glu Val Gln Thr Ala Leu His Ser Glu Ile Thr Ala Ala Leu Ser
 340 345 350

30 cct ggc tcc agt gcc tac ccc tca gcc act gtt etg tcc cag ctg ccc 1225
 Pro Gly Ser Ser Ala Tyr Pro Ser Ala Thr Val Leu Ser Gln Leu Pro
 35 355 360 365

40 ctg ctg aag gcg gtg gtc aag gaa gtg cta aga ctg tac cct gtg gta 1273
 Leu Leu Lys Ala Val Val Lys Glu Val Leu Arg Leu Tyr Pro Val Val
 370 375 380

45 cct gga aat tct cgt gtc cca gac aaa gac att cat gtg ggt gac tat 1321
 Pro Gly Asn Ser Arg Val Pro Asp Lys Asp Ile His Val Gly Asp Tyr
 385 390 395 400

50 att atc ccc aaa aat acg ctg gtc act ctg tgt cac tat gcc act tca 1369
 Ile Ile Pro Lys Asn Thr Leu Val Thr Leu Cys His Tyr Ala Thr Ser
 405 410 415

55

5 agg gac cct gcc cag ttc cca gag cca aat tct ttt cgt cca gct cgc 1417
 Arg Asp Pro Ala Gln Phe Pro Glu Pro Asn Ser Phe Arg Pro Ala Arg
 420 425 430

10 tgg ctg ggg gag ggt ccc acc ccc cac cca ttt gca tct ctt ccc ttt 1465
 Trp Leu Gly Glu Gly Pro Thr Pro His Pro Phe Ala Ser Leu Pro Phe
 435 440 445

15 ggc ttt ggc aag cgc agc tgt atg ggg aga cgc ctg gca gag ctt gaa 1513
 Gly Phe Gly Lys Arg Ser Cys Met Gly Arg Arg Leu Ala Glu Leu Glu
 450 455 460

20 ttg caa atg gct ttg gcc cag atc cta aca cat ttt gag gtg cag cct 1561
 Leu Gln Met Ala Leu Ala Gln Ile Leu Thr His Phe Glu Val Gln Pro
 465 470 475 480

25 gag cca ggt gcg gcc cca gtt aga ccc aag acc cgg act gtc ctg gta 1609
 Glu Pro Gly Ala Ala Pro Val Arg Pro Lys Thr Arg Thr Val Leu Val
 485 490 495

30 cct gaa agg agc atc aac cta cag ttt ttg gac aga tagtcccatg 1655
 Pro Glu Arg Ser Ile Asn Leu Gln Phe Leu Asp Arg
 500 505

35 gaaagagact gtcacatca ccctttcatt catcataggg ataagatttt ttgtaggcac 1715

40 aagaccaagg tatacatctt ccctaatagc ctatctgacc aaactggata gaaccaccat 1775

45 agtgaagtgt gaggcggccc tgaccaatgt gtgaagtatg cacttggcct gactcaggaa 1835

50 gccaggtgag aaaaccatgg tctctctgct tgcttggccc ttctgatcat giatgcatcc 1895

55 cccaaggatg aatcagatt ttaactaata atgctggatg gcctgaggaa agattcaact 1955

gcctctcttt ttgggtttc atagtgttca ttgatgtgc tggctaagca ttatcaaag 2015

cataagctca gtaactgtgc atctggctg tacctggtag gtccttcgic ttgcatgta 2075
 5 agctctttga gaggaagggt gaagccttat ttgtttttta tgcctccctgc cagggcctgt 2135
 ctctgactag gtgtcaccat acacattctt agattgaatc tgaacctgt ggcagaaggg 2195
 10 ataagcagct tacttagtag gctctgtcta ccccttccct tctttgtctt gcccttagga 2255
 aggtgaatct gccctagcct ggtttacggt ttcttataac tctcctttgc tctctggcca 2315
 15 ctattaagtg ggtttgcccc atcacttagt tctcaggcag agacatcttt gggcctgtcc 2375
 ctgcccaggc ctctggcttt ttatattgaa aattttttaa tattcacaaa ttttagaata 2435
 20 aatcaaatat tccattaaaa aaaaaaaaaa aaaa 2469

25

SEQ ID NO: 7

30

<211> 23

<212> DNA

<213> synthetic DNA

35

<400> 7

ctsctsaarg chgtsatyaa rga

23

40

SEQ ID NO: 8

45

<211> 22

<212> DNA

<213> synthetic DNA

50

<400> 8

ckcttbccra abccraargg va

22

55

SEQ ID NO: 9

<211> 25

<212> DNA

<213> synthetic DNA

<400> 9

aaggcagtga ttaaggaagt gttga

25

Claims

1. A polypeptide comprising an amino acid sequence selected from the amino acid sequences represented by SEQ ID NOS.1 and 2, or
 a polypeptide having 25-hydroxyvitamin D₃-1 α -hydroxylase activity and comprising an amino acid sequence which deviates from the amino acid sequences represented by SEQ ID NOS: 1 or 2 by the deletion, substitution and/or addition of one or more amino acid residues.
2. A DNA encoding a polypeptide according to claim 1 or
 a DNA which hybridizes with said DNA under stringent conditions.
3. The DNA according to claim 2, wherein the DNA is DNA comprising a nucleotide sequence selected from nucleotide sequences represented by SEQ ID NOS.3 and 4.
4. A recombinant DNA prepared by inserting the DNA according to claim 2 or 3 into a vector.
5. A transformant carrying a recombinant DNA according to claim 4.
6. A method for producing 25-hydroxyvitamin D₃-1 α -hydroxylase or a polypeptide having 25-hydroxyvitamin D₃-1 α -hydroxylase activity, comprising:
 cultivating the transformant according to claim 5 in a medium to produce 25-hydroxyvitamin D₃-1 α -hydroxylase in the culture; and
 recovering said 25-hydroxyvitamin D₃-1 α -hydroxylase from the resulting culture.
7. A method for producing 1 α , 25-dihydroxyvitamin D₃, comprising:
 putting the polypeptide according to claim 1 and 25-hydroxyvitamin D₃ in an aqueous medium to produce 1 α , 25-dihydroxyvitamin D₃ in the aqueous medium; and
 recovering said 1 α , 25-dihydroxyvitamin D₃ from the aqueous medium.
8. An antibody recognizing the polypeptide according to claim 1.
9. A method for immunologically detecting a polypeptide having 25-hydroxyvitamin D₃-1 α -hydroxylase activity, using the antibody according to claim 8.
10. An immuno-histological staining method comprising using an antibody according to claim 8.
11. An immuno-histological staining agent containing an antibody according to claim 8.

12. 25-hydroxyvitamin D₃-1 α -hydroxylase polypeptide or a polypeptide having 25-hydroxyvitamin D₃-1 α -hydroxylase activity obtainable by the method of claim 6.
- 5 13. A pharmaceutical composition comprising the polypeptide of claim 1 or 12, the DNA of claim 2 or 3, and/or the recombinant DNA of claim 4, or the antibody of claim 8, and, optionally, a pharmaceutically acceptable carrier and/or diluent.
- 10 14. A diagnostic composition comprising the polypeptide of claim 1 or 12, the DNA of claim 2 or 3, the recombinant DNA of claim 4, and/or the antibody of claim 8 and optionally suitable means for detection.
- 15 15. Use of the polypeptide of claim 1 or 12, the DNA of claim 2 or 3, and/or the recombinant DNA of claim 4 for the preparation of a pharmaceutical composition for preventing or treating a disease characterized by a decrease of active type vitamin D₃.
16. The use of claim 15, wherein said disease is osteoporosis.
17. A kit comprising:
- 20 (a) the polypeptide of claim 1 or 12;
(b) the DNA of claim 2 or 3;
(c) the recombinant DNA of claim 4; and/or
(d) the antibody of claim 8.

25

30

35

40

45

50

55




Fig. 1

This Page Blank (uspto)

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☒ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☒ **FADED TEXT OR DRAWING**
- ☒ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☒ **SKewed/SLANTED IMAGES**
- ☒ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.

This Page Blank (uspto)